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ABSTRACT
MAGNETIC FIELD-INDUCED INTRAMOLECULAR
CYCLIZATION AS A TRIGGER FOR NANOPARTICLEBASED DELIVERY SYSTEMS
Sara Katherine Biladeau
July 11, 2017
Magnetic nanoparticles (MNPs) are used in a variety of applications, including as
agents for magnetic resonance imaging, generation of local hyperthermia, and as
platforms for drug delivery. Iron-based MNPs are often coated with a shell, such as silica
or gold, to increase biocompatibility for drug delivery applications. Many MNPs used
for cancer therapy rely on either an internal trigger, such as a difference in pH, or an
external trigger, such as light or an alternating magnetic field (AMF), to cause release of
a payload, typically a chemotherapeutic drug. Internal triggers are appealing because
drug release can be targeted to a tumor environment, but a major drawback is untriggered
release, or release prior to reaching the targeted area.

To address the problem of

untriggered release, researchers have explored the use of thermally responsive triggers on
iron oxide nanoparticles. In these cases, payload release occurs as a result of local
hyperthermia that is induced by application of an alternating magnetic field. NP-linkerdrug motifs containing an azo functionality or a substructure prone to retro-Diels Alder
reaction are examples of thermally responsive triggers. This thesis work expands AMFmediated drug delivery by demonstrating a new mechanism for substrate release:
intramolecular cyclization of a linking tether between payload and nanoparticle.
Described is a linker system (LS) fitted with a thiol moiety, a secondary amine, carbonate
v

functionality, and a payload. Attachment of the linker system to gold-coated iron oxide
nanoparticles delivers a thermally responsive drug delivery system (Fe@Au-LS-drug).
On exposure to an AMF, the magnetic nanoparticles generate heat that powers
cyclization of the amine onto the carbonate for payload release to occur. The cyclization
mechanism was confirmed by synthesis and testing of an amine-free linker to rule out
carbonate hydrolysis as the mode of payload release. Testing the system with a watersoluble fluorophore as payload showed 40% release in response to AMF application with
minimal release from the amine-free linker under identical conditions. Payload release
could be increased to nearly 100% by addition of PEG-coated iron oxide nanoparticles as
a means to increase local hyperthermia. This work shows for the first time that the highly
flexible process of intramolecular cyclization can serve in conjunction with magnetic
iron-gold nanoparticles as a delivery system trigger for externally triggered applications.
Chapter 1 reviews the role of iron oxide nanoparticles in delivery applications and
summarizes the challenges of drug delivery using various internally and externally
responsive linkers. Chapter 2 describes different methods for gold-coated iron oxide
nanoparticle preparation and the challenges of such core-shell syntheses. Chapter 3
focuses on the synthesis of an amine-based linker system designed for AMF-mediated
payload release. Synthesis of the analogous control linker is also described. Chapter 4
describes studies using an AMF to cause payload release from Fe@Au-LS NPs. Chapter
5 presents all experimental procedures and the characterization data for key
intermediates, as well as a brief synopsis of previous synthetic work unrelated to this
project.
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1.1.

INTRODUCTION
Nanoparticles (NPs) can be prepared using a variety of different organic or

inorganic materials, including lipids,1 gold,2 and iron oxide.3 Common applications of
NPs include water purification,4 catalysis,5 and as a platform for drug delivery.6 To be
most effective in vivo, NPs must have a hydrodynamic size between 10-100 nm.7 The
kidneys filter NPs smaller than 10 nm, and the immune system removes NPs greater than
100 nm via phagocytosis. Of particular interest to us are iron oxide NPs, which are made
of Fe3O4 or the oxidized form γ-Fe2O3. Both of these oxides are magnetic. Researchers
have exploited the magnetic properties of Fe3O4 NPs in a variety of ways, particularly in
magnetic resonance imaging,8 induction of hyperthermia,9 and drug delivery.4
Magnetic resonance (MR) imaging is a common practice for non-invasive
examination of the body. Similar to proton nuclear magnetic resonance, MR imaging
relies on the alignment, excitation, and subsequent relaxation of the protons of water
molecules within the body. Protons of water molecules within different tissues have
different relaxation times, which allows for contrast between tissues within the body.
After excitation, relaxation occurs in the x-, y-, and z-axes. Contrast agents can be
administered to give a better image of certain tissues by changing the relaxation time of
the protons.

Gadolinium chelates alter the longitudinal (T1) relaxation rate of

surrounding water molecules along the z-axis. At low concentrations, they increase the
relaxation time of T1.

This provides positive enhancement, which leads to greater

contrast, meaning a brighter spot (Figure 1.1a).10 Iron oxide NPs less than 30 nm alter
the transverse (T2) relaxation rate along the xy-axis of surrounding water molecules.11
They provide negative contrast, and are seen in the image as a dark spot (Figure 1.1b).12
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a

b
Figure 1.1. MRI contrast agents. a. Murine SV11 brain tumor
immediately before (left) and after (right) gadolinium-based
contrast injection. Adapted with permission from J. Immunol.
2000, 165, 7293-7299. Copyright 2000 The American Association
of Immunologists, Inc. b. Iron oxide NP accumulation in murine
lymphoma. Adapted with permission from NMR Biomed. 2004,
17, 484-499. Copyright 2004 John Wiley and Sons.
Another appealing quality of iron oxide NPs is their ability to generate local
hyperthermia upon exposure to an alternating magnetic field (AMF). An AMF is created
by an alternating current, which is a current that reverses its direction many times a
second at regular intervals.

Currents produce magnetic fields, and when a current

alternates its direction, the direction of the magnetic field also flips. Once a current is
established, the current forms a magnetic field and the magnetic NPs align with it. The
current is not static though; it constantly flips 180°, which oscillates the magnetic field.
Because the NPs are magnetic, they will attempt to realign with the field as it oscillates,
and their movement generates local hyperthermia, as seen in Figure 1.2.

3

Figure 1.2. Methods of local hyperthermia generation upon exposure to an AMF.

Heat from exposure to an AMF is generated through a hysteresis loss, which is the
reversal of the NPs as a whole. This can be broken down into two different models:
Néelian relaxation and Brownian relaxation. Néelian relaxation is due to the individual
movement of each nanoparticle dipole, whereas Brownian relaxation is due to the
physical rotation of the nanoparticle itself.13 The heat generated is quantified as specific
loss power (SLP) or specific absorption rate (SAR). These terms are interchangeable
because both are measurements of heat dissipation per unit mass of magnetic
nanoparticles in an AMF.14 This value can vary depending on a variety of factors, such
as NP size, 15 viscosity of supernatant, 16 magnetic field strength and frequency, 17
concentration,11 and polydispersity.18
Local hyperthermia is especially important in some forms of cancer therapy.
Solid tumor cells have poor vasculature that leads to hypoxia and low pH, making
cancerous cells more susceptible to hyperthermia.19 Increased temperatures in or near
tumor cells, generally between 40 °C and 45 °C, can lead to apoptosis, or cell death. This

4

rise in temperature does not affect most healthy cells because their structured vasculature
allows for better heat dissipation (up to 20 times increased blood flow in healthy tissue
versus 2 times increased blood flow into cancerous cells).13 In addition, healthy cells
produce heat shock proteins on exposure to local hyperthermia. Heat shock proteins
(HSP) allow proteins to refold after denaturation caused by a rise in temperature, or heat
shock. Cancerous cells overexpress heat shock proteins and present them on the surface
of the cell, which then are easily lysed by killer T-cells.19 Finally, local hyperthermia as
an adjuvant therapy increases a cell’s susceptibility to radiation treatment post AMF
application, as seen in Table 1.1. If the temperature within a cell reaches above 45 °C,
cell ablation occurs. At this temperature, both healthy and cancerous cells are affected,
and prolonged exposure causes necrosis.20

Tumor
Lymphnodes of
head and
neck
Breast
Lung

Treatment

Patients

Effect with
hyperthermia
(complete remission)

Radiotherapy

41

83%

Effect without
hyperthermia
(complete remission)
41%

Radiotherapy
306
59%
41%
Chemotherapy
44
68%
36%
Radiotherapy,
Bladder
102
94%
67%
Surgery
Table 1.1. Various tumor treatments with or without adjuvant thermotherapy. The dual
therapy shows an increase in number of patients in complete remission after primary
treatment with adjuvant hyperthermia treatment versus without hyperthermia. Adapted
with permission from Ann. Oncol. 2002, 13, 1173-1184. Copyright 2002 Oxford
University Press.
The first study utilizing localized hyperthermia generation for prostate cancer was
done in Germany over 10 years ago.21 Johannsen et al. injected iron oxide NPs with an

5

aminosilane-type shell into the prostate of a 67 year-old man with locally recurrent
prostate cancer and exposed him to an AMF (Figure 1.3). The temperature of the
prostate rose between 40 °C and 48.5 °C during the first treatment. Six weeks after NP
injection, AMF treatment was repeated without new injection and the intraprostatic
temperature was between 39.4 °C and 42.5 °C.

Figure 1.3. Alternating magnetic field applicator for human use
(MFH300F, MagForce® Nanotechnologies GmbH, Berlin).
Adapted with permission from Int. J. Hyperthermia 2005, 21, 637647. Copyright 2005 Taylor and Francis Group.
Local hyperthermia can be effective for cancer treatments, but it is often difficult to
completely eradicate the tumor, especially in the case of prostate cancer, where the
distribution of NPs is poor. Despite the initial shortcomings, Johannsen et al.22 continued

6

to evaluate the quality of life after iron oxide NPs hyperthermia treatments. They found
no significant impairment of the quality of life. The coated iron oxide NPs had no
systemic toxicity, but, as seen before, the distribution of NPs within the prostate was
poor. This created hotspots within the tumor, up to 55 °C, and thus necessitated that the
power of the AMF be significantly lowered compared to other studies (i.e., 4-5 kA/m for
prostate versus 10-14 kA/m for brain tumors) to limit discomfort and skin reactions. Of
the 15 most commonly used FDA-approved nanotherapeutics in the past 20 years, few
involve using only iron oxide NPs, and none appear to use hyperthermia as the foremost
method for cancer eradication (Table 1.2).
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Trade
Name
Exparel
Oncospar

Indication

Initial
Approval
Date

Severe Combined Immunodeficiency
Disease*

1990

Acute Lymphoblastic Leukemia

1994

Formulation
Pegylated
Adenosine
Deaminase
Pegylated
Asparaginase

Doxil

Liposomal
Doxorubicin

Kaposi’s Sarcoma, Ovarian Cancer,
Metastatic Breast Cancer*

1995

Abelcet,
Amphotec,
Ambisome

Liposomal
Amphotericin B

Fungal Infections

1995,
1996,
1997

Multiple Sclerosis

1996

Oral Contrast Agent

1997

Hepatitis C

2001

Hepatitis B, C

2002

Chemotherapy-induced Neutropenia

2002

Advanced lung, pancreatic, breast
cancers

2005

Anemia of Chronic Kidney Disease

2007

Lymphomtous Meningitis

2007

Post-operative Pain

2011

Sentinal Lymphnode Mapping*

2011

Adult Acute Myelogenous Leukemia

2012

Copaxone
Ferumoxsil
PegIntron
Pegasys
Neulasta
Abraxane
Feraheme
Depocyte
Exparel
Sienna+
Marquibo

Glutaramer
Acetate
Siloxane-Coated
Iron Oxide
Pegylated
Interferon α-2b
Pegylated
Interferon α-2a
Pegylated
Filgastrim
Albumin Bound
Paclitaxel
CarbohydrateCoated Iron
Oxide
Liposomal
Cytarabine
Liposomal
Bupivacaine
Dextran-Coated
Iron Oxide
Liposomal
Vincrisitine

Table 1.2. Most commonly used FDA-approved nanotherapeutics; highlighted entries
show use of iron oxide NPs. * indicate approval by European Regulatory Agency but not
FDA. Adapted with permission from Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.
2017, 9, 1416. Copyright 2017 John Wiley and Sons.
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Current nanotherapeutics and clinical studies focus on delivery of chemotherapeutic
drugs in a NP formulation. 23 Many clinicians believe that NP formulation of drugs will
decrease systemic toxicity as well as increase efficacy. To date, only the former has been
proven true. In the case of NP-mediated hyperthermic treatment of cancer, it appears
likely that a combination of local hyperthermia and drug delivery will be necessary for
optimal cancer eradication – this is the basis of the present thesis work.
Iron oxide NPs are an ideal platform for drug delivery. However, direct binding
of drugs to iron oxide NPs is not common because of the limited reactivity of the NP
surface.

As a result, iron oxide NPs are often coated with a shell. In one example,

Mattingly et al.24 used a surrounding cationic lipid bilayer to host small molecules, such
as doxorubicin (Dox), an anti-cancer agent (Figure 1.4). Efficacy of this system was
explored using in vitro studies on MCF-7 breast cancer cells. After incubation at 37 °C
for 2 hours, the magnetic liposomes released Dox and caused >90% cell death. Other
common coatings include silica or gold. Core-shell NPs of this type will be discussed in
greater detail later in this chapter.

9

Figure 1.4. Magnetic liposomes for drug delivery. Dox
release and >90% cell death was seen after incubation at 37
°C for 2 hours. Adapted with permission from Langmuir
2015, 31, 3326-3332. Copyright 2015 American Chemical
Society.
Several researchers have exploited the local hyperthermia generated by iron oxide
NPs upon exposure to an AMF as a mechanism (i.e., trigger) for drug release. A popular
coating for iron oxide NPs is mesoporous silica (Figure 1.5). Thomas et al.25 designed
mesoporous silica NPs with zinc-doped iron oxide as the core. A “thread” (consisting of
N-(6-N-aminohexyl)aminomethyltriethoxysilane) was chemically attached to the inside
of the pores, followed by drug loading within the pores of the silica NPs. The pores then
were capped with cucurbit[6]uril, which is a macrocycle that interacts electrostatically
with the “thread” molecule to prevent drug release. Upon exposure to an AMF, the
generated local hyperthermia helped the caps to overcome their attraction to the “thread”
molecules, and the drug then escaped the pores.
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Figure 1.5. Mesoporous silica NPs for drug delivery. Doxorubicin is loaded into pores
that then were sealed by addition of a “cap” (4). Upon exposure to an AMF (5), the cap
is displaced and the drug is released. Adapted with permission from J. Am. Chem. Soc.
2010, 132, 10623-10625. Copyright 2010 American Chemical Society.

In another example, thermoresponsive hybrid nanogels were prepared by Cezar et al.26
This group designed a ferrogel from alginate and iron oxide NPs to be solid at room
temperature (Figure 1.6, left). After exposure to an AMF (Figure 1.6, right), the hydrogel
deforms. The biphasic hydrogel was loaded with mitoxantrone, an antineoplastic agent,
through ionic interactions with alginate. Deformation of the hydrogel led to diffuse drug
release with cumulative therapeutic doses up to 95 µg.
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Figure 1.6. Biphasic hydrogel for drug release. After synthesis, the gel remains solid
(left), but upon exposure to an AMF, the hydrogel deforms and releases its payload.
Adapted with permission from Adv. Heathc. Mater. 2014, 3, 1869-1876. Copyright 2014
John Wiley and Sons.
1.2.

PREPARATION METHODS
Iron oxide NPs can be prepared in a variety of ways. One simple, highly used

method is co-precipitation of iron salts.27 This method relies on the addition of the iron
salts Fe2+/Fe3+ in a 2:1 ratio to a basic aqueous medium to yield Fe3O4. The method is
straightforward, is done within minutes, and gives high yields of NPs. However, poor
shape control, oxidation, and aggregation are all problems associated with the coprecipitation method. Riaz et al.28 explored the size and shape of iron oxide NPs in
relation to pH by varying the amount of sodium hydroxide in solution. At low pH (pH =
2), the NPs had diameters of 25 nm, while at high pH (pH =10), the NPs had diameters of
100 nm. At pH = 8, the Fe3O4 NPs were non-uniform, varying 50-100 nm in diameter.
A former colleague in the Nantz group, Dr. Stephanie Mattingly, measured particle
surface charge by varying washing steps after NP synthesis and isolation and then
examined the NP zeta potential. 29

Different washing methods, such as dilute

hydrochloric acid versus neutral water, significantly altered the resultant NP surface
charges. Rinsing once with neutral water after the co-precipitation method gave anionic
NPs, while rinsing with dilute hydrochloric acid gave positively charged NPs, as might

12

be expected. NPs that have a surface charge tend not to aggregate because of ionic
repulsion. When the NPs were rinsed multiple times with neutral water, as is often
described in Methods sections of literature preparations, the NPs had a neutral charge,
which can lead to aggregation. To help achieve monodispersion and avoid aggregation, a
thermal decomposition method was developed.30 This method is performed in nonaqueous media and coats the NPs with an organic ligand, which decreases aggregation.
NPs made in this way also have a very narrow size distribution, good shape control, and
relatively high yields. Unlike the co-precipitaiton method, the reaction requires high
temperatures (e.g., 210 °C-320 °C), an inert atmosphere, and longer reaction times. Also,
because the reaction is not performed in water, further steps are necessary to make the
resultant NPs water-soluble.31 Other methods for NP synthesis include microemulsion32
and hydrothermal syntheses. 33

1.3.

SURFACE MODIFICATIONS
In addition to the need for shells to enable convenient substrate attachments, other

problems have been noted using “naked” iron oxide NPs. Without surface modification,
iron oxide NPs are degraded into ferrous Fe (II) and ferric Fe (III) by the liver or spleen34
or cause oxidative stress, as seen in in vivo studies by Chahinez et al. 35 Surface
modifications allow for biocompatibility, and often include organic ligands, such as
polyethylene glycol (PEG)36 and chitosan,37 or inorganic coatings, such as silica38 or
gold. 39 These modifications change the iron oxide surface, which allows for the
attachment of a variety of molecules, such as drugs, targeting agents, or antibodies.
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Silica is widely used to modify iron oxide NPs because it is hydrophilic, which
aids in aqueous solvation, it helps prevent aggregation through electrostatic repulsions,
and it provides a surface that is more amenable to attachment of molecules.40 One of the
most popular methods to coat iron oxide with silica is the Stöber method38 in which the
iron oxide nanoparticles are dispersed in a water/ethanol solution. Formation of the silica
shell happens after hydrolysis of a silica precursor, such as tetraethoxysilane (TEOS),
followed by condensation of the siloxane onto the surface of the iron oxide NPs. This
method is attractive because the silica shell thickness can be fine-tuned based on the
amount of alkoxysilane added.41 Recent examples of silica-coated iron oxide NPs in drug
delivery include work by Hwang et al.,42 Moorthy et al.,43 and Zhang et al.44
Gold nanoparticles are also widely employed in drug delivery because gold is an
inert noble metal with excellent biocompatibility. Gold is becoming popular as a shell
coating of iron oxide NPs principally for this reason, although the ease of attachment of
substrates via thiol methodology is another strong driving force.45 Iron oxide-gold coreshell (Fe@Au) NPs can be synthesized in a few ways, namely a bilayer method via
aqueous or thermal decomposition, or a multilayer method using a “glue” molecule to
attach a gold shell.39 In the aqueous bilayer method, the iron oxide core is combined with
chloroauric acid (HAuCl4) and the gold is reduced chemically. Common reducing agents
include sodium borohydride,46 citrate,47 and ascorbic acid.48 A second common bilayer
method is thermal decomposition, where hydrophobic iron oxide NPs are combined with
oleic acid, oleyl amine, and gold (III) acetate, then heated in a high boiling organic
solvent.49 This method does require further modification to the shell to make the Fe@Au
NPs water-soluble. Though prevalent in the literature, bilayer methods are challenging
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because of the difficulty of gold deposition on the iron oxide core, as well as the
formation of gold nanoparticles (GNPs) in the process of shell formation. To overcome
this challenge, researchers have explored the use of molecules that strongly attach to both
iron oxide and gold to serve as a “glue” that binds the metals together. Often, this
method involves using gold nanoseeds in the form of amine-terminated molecules as
nucleation points onto which the gold can reduce. After synthesis, ligands that can bind
to the gold shell, namely amines or thiols, both of which form strong bonds with gold,50
are added to coat the NP surface.

1.4.

DRUG DELIVERY CHALLENGES
Drug delivery systems utilize a stimulus to deliver a drug at a specific time and

location within the body to avoid side effects due to systemic distribution. A common
chemotherapeutic agent used in the treatment of cancer is Dox, which induces apoptosis
in replicating cells.51 The cells that are affected the most are rapidly growing cancer
cells, but rapidly growing non-cancerous cells are affected as well. When administered
intravenously, common side effects include hair loss and digestive issues. A serious side
effect of Dox in large quantities (i.e., 500-600 mg/m2) includes myocardial toxicity,
which can lead to congestive heart failure or death.52 Because of these limitations, better
spacial and temporal drug delivery is the next step in cancer treatment. Precise delivery
of drugs to cancer cells, so that healthy cells are minimally affected, reduces the side
effects seen with systemic distribution. Because of this, the Dox dosage loaded onto a
nanoparticle can be decreased because healthy cells are not destroyed as they were with
systemic distribution. In what we believe will be a key advance, Dox tethered to iron
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oxide NPs can be used in combination with thermotherapy – cancer cells are more
susceptible to chemotherapy after thermotherapy.19
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Scheme 1.1. Common conjugations of Dox. Dox can react with a primary amine (R, R’
= carbon), hydrazine (R = NH, R’ = carbon), or acyl hydrazine (R = NH, R’ = acyl) to
form an imine, hydrazone, or acyl hydrazone, respectively.
Dox attachment to NPs can be through ionic interaction or covalent bonds.53 Of
particular interest to us is covalent attachment. One way to load Dox onto NPs
conveniently is through its C(13) carbonyl moiety (Scheme 1.1). A hydrazine compound
can react with Dox to form a hydrazone linkage, which cleaves under acidic conditions.
This is an ideal internal stimulus, since the area surrounding cancer cells is slightly more
acidic, pH 5-6, than physiological conditions, pH 7.4. 54 Aryal et al. 55 attached an
equimolar amount of PEG-thiol and DOX-acyl hydrazone to gold nanoparticles (Figure
1.7a) and showed 80% Dox release after 5 hours at pH 5.3. Mohammad et al.56 attached
Dox to Fe@Au via cysteamine to form an imine (Figure 1.7b), which are cleaved in
acidic conditions as well. Release of Dox is seen, but only 56% is seen at the extremely
low pH of 2.1 after 3 hours. They also performed Dox release studies at pH 2.1 using
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AMF at various power settings, where the highest setting (430 Hz) released 72% Dox
after 3 hours.
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Figure 1.7. a. Dox attached to gold NPs via acyl hydrazone linkage. After 5 hours at pH
5.3, 80% release was seen. Adapted with permission from J. Mater. Chem. 2009, 19,
7879-7884. Copyright 2009 Royal Society of Chemistry. b. Dox attached to Fe@Au
NPs via imine bond. At extremely low pH with application of an AMF at 430 Hz, 72%
release was seen. Adapted with permission from J. Colloid Interface Sci. 2014, 434, 8997. Copyright 2014 Elsevier.
Despite the appeal of internally triggered drug release, it is not ideal. In each of
the above “internal release” studies, Dox escape from the carrier was seen, even at
physiological pH (10% for Aryal and 30% for Mohammad). This problem of untriggered
release is critical. If NPs are injected into patients intravenously, they passively pool in
the tumor though the enhanced permeation and retention (EPR) effect.

Enhanced

permeation is caused by leaky vasculature of the tumor cells, and retention is due to poor
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lymphatic drainage.57 The pooling process is not instantaneous; it takes time for blood to
circulate and NPs to retain near the tumor. As the NPs circulate, though, they release
drugs in a systemic type fashion rather than only near tumor cells. The advantage in
using a delivery system is lost. The payload released during circulation may or may not
kill cancer cells as intended (i.e., they are likely to affect other rapidly growing, healthy
cells, as seen in systemic distribution), meaning more drug must be loaded onto the NPs
to deliver the initial intended dosage to the target area. This, in turn, would lead to a
greater concentration of untriggered release systemically, making this delivery system
only slightly better than systemic chemotherapeutic distribution.
Because an internal trigger cannot be easily controlled, the use of an external
trigger, such as an AMF, is needed for precise payload release. One such method is the
use of a thermally labile group that would release payload upon triggering. In recent
years, researchers have explored the azo functionality58,59 as well as a retro-Diels Alder
reaction60,61 for payload release, as discussed below.
The azo functionality decomposes at high temperatures, generally above 150 °C.62
The mechanism for azo decomposition is through a radical reaction, as outlined in
Scheme 1.2.63 There are 3 stages in a radical reaction: initiation, propagation, and
termination. Radical formation is initiated by heat generated upon NP exposure to AMF,
creating a carbon and nitrogen radical (Scheme 1.2a). In the next step, a new radical is
formed and nitrogen is expelled (Scheme 1.2b).

Termination is caused by the

combination of two free radical molecules to form a new bond (Scheme 1.2c, d).
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Scheme 1.2. Thermal decomposition of azo functionality. a.
Initiation of radical formation is caused heat to form a carbon
and nitrogen radical. b. The nitrogen radical reacts to expel N2
and a new carbon radical. c, d. Termination occurs when
radicals combine to form new bonds. Adapted with permission
from Int. J. Chem. Kinet. 1984, 16, 767-779. Copyright 1984
John Wiley and Sons.
Researchers have already explored the use of thermally labile linkers attached to
iron oxide NPs for payload release. Riedinger et al.58 first explored the distance at which
an azo moiety would decompose when iron oxide NPs were exposed to an AMF. For
ease of detection, they initially used fluoresceineamine, then Dox after optimization.
Each step of the linker was built onto the NP, as opposed to complete synthesis first, with
attachment to the NP last.
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2013, 13, 2399-2406. Copyright 2013 American Chemical Society.

As seen in Scheme 1.3, gallic acid was derivatized with different lengths of PEG for
attachment to iron oxide NPs, then the azo functionality was attached followed by
attachment of the fluorophore via an amide bond. The length of spacer between the NP
and the azo functionality did not significantly change the amount of azo decomposition
when held at a constant temperature. When the NP-linker system was exposed to an
AMF for 1 hour, the shorter PEG spacer released more fluorophore. It can be inferred
from the data that the carbon-based free radicals formed did not combine as seen in
Scheme 1.2d. If this were so, the fluorophore would remain on the NP and would not
show release. The fluorescence release data for the shorter PEG spacer corresponded to a
larger change in temperature compared to the longer PEG spacer (i.e., 40 K vs 10 K
difference at 13.5 kA m-1 and 334.5 kHz). Their studies also showed a significant local
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temperature change was detected 0-3 nm from the surface of the iron oxide NP, with
significant exponential decay as the distance increased. More recently, Romero et al.59
used thermal decomposition of a short linker with an azo group for rapid release of a
fluorescent dye, CG633. Upon exposure to an AMF (500 kHz and 15 kA m-1), nearly
entire release was seen after only 10 seconds for NPs with a diameter of 20 nm. This
technology was used to release a pharmacological agent, allyl isothiocyanate, for neuron
excitement. After exposure to an AMF, rapid Ca2+ influx was noted, indicative of neuron
excitation.
In another strategy, N’Guyen et al.60 designed a retro-Diels Alder (DA) linker for
delivery of a fluorophore, rhodamine, without inducing a significant temperature increase
to the bulk solution. At higher temperatures, the synthesized linker undergoes retro-DA
reaction. The requisite higher temperature is induced when NPs are exposed to an AMF.
The linker design is shown in Scheme 1.4. The linker was synthesized prior to loading
on the iron oxide NPs, with installation of the fluorophore performed after linker loading.
A phosphonic acid ligand was used for attachment to iron oxide NPs (4, Scheme 1.4). A
hydrophilic polymer was attached to the linker via a 1,3-dipolar cycloaddition. The azide
was attached to the polymer, and the alkyne was attached to the linker. Under typical
copper-catalyzed azide-alkyne cycloaddition, the two moieties reacted in 3+2 fashion to
form the corresponding triazole (2, Scheme 1.4). Rhodamine was attached via DA (5,
Scheme 1.4) with 85 % attachment confirmed via NMR analysis. The loaded NPs were
exposed to AMF (frequency 332.5 kHz, magnetic field strength 11.3 kAm-1) for 10
minutes. Release of 3 % and 5 % for 2.5 x 10-3 wt % and 2.5 x 10-3 wt %, respectively,
could be seen without any significant increase in bulk solution temperature.
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Scheme 1.4. Synthesis of a retro-DA linker with hydrophilic polymer attachment via
1,3-dipolar cycloaddition and DA for fluorophore attachment onto iron oxide NPs.
Adapted with permission Angew. Chem. Int. Ed. 2013, 52, 14152-14156. Copyright
2013 John Wiley and Sons.
In another example, Hammad et al.61 designed a retro-Diels Alder (DA) linker for
delivery of Dox. The linker-drug was attached to Zn0.4Co0.6Fe2O4@Zn0.4Mn0.6Fe2O4
core/shell NPs by means of alendronic acid-iron interactions. The zinc-cobalt and zincmanganese doped NPs have a higher SAR than pure iron oxide NPs, meaning they have
enhanced magnetic heat inducing properties and induced local hyperthermia to a greater
extent. Their linker design favors formation of a DA product at lower temperatures by
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utilizing furan and maleimide as the diene and dieneophile, respectively. As seen with
retro-DA linker design by N’Guyen et al., higher temperatures caused the linker to
undergo a retro-DA reaction. The requisite higher temperature can be induced when NPs
are exposed to an AMF. The linker design is shown in Scheme 1.5. Like with Reidinger
et al., the linker was synthesized directly on the iron oxide NPs rather than complete
synthesis of the linker prior to attachment. Alendronic acid served as the means for
attachment to NPs (2, Scheme 1.5) and Dox was attached via an amide bond (5, Scheme
1.5) with confirmation of loading via FT-IR analysis. The loaded NPs were exposed to
AMF (frequency 1950 kHz, power 6200 W) for 5 minutes. The temperature of the
solution reached 50 °C after 5 minutes of exposure to the AMF and remained at 50 °C for
10 minutes after exposure was ceased. Dox release was ~45% after the 5 minutes of
exposure to AMF, and release increased to greater than 90% Dox release in the 10
minutes after AMF exposure was stopped. This work with thermally labile linkers
ultimately encouraged our pursuit of a short linker that would require significant thermal
energy for rapid payload release.
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1.5.

HYPOTHESIS
Combining local hyperthermia treatment with drug delivery by using a single

agent to accomplish both tasks is the next generation of cancer treatment. The use of a
thermally labile linker attached to biocompatible NPs, specifically Fe@Au NPs, to
release a payload based on an external stimulus such as AMF is not prevalent in literature
and should be explored in greater depth and breadth.

We designed a thermally

responsive linker for attachment to Fe@Au NPs which utilized the ability of iron oxide
NPs to create a local hyperthermia upon exposure to AMF.

The generated local

hyperthermia promoted intramolecular cyclization and caused linker cleavage (i.e., drug
delivery) as seen in Figure 1.8, thus providing thermotherapy and drug delivery
simultaneously. The following chapters discuss work associated with this hypothesis.
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Figure 1.8. Overall pictoral representation of thesis work. I: Fe@Au NPs, II: Dual NP
system of gold NPs and water-soluble iron oxide NPs. Left panel: NPs at physiological
temperature (37 ºC), no release of payload. Middle panel: Application of AMF to
induce local hyperthermia of iron oxide, bulk solution temperature 40-45 ºC. Right
panel: Payload released from NPs into solution.
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2.1.

INTRODUCTION

core shell

Fe3O4

Fe@Au
Au
Figure 2.1. Gold-coated iron oxide nanoparticle.

Gold-coated iron oxide NPs (Fe@Au, Figure 2.1) can be synthesized in a variety
of ways.1, 2 The medium in which the gold coating is applied can be either aqueous or
organic, and the coating can be either deposited directly onto an iron oxide core or
indirectly, by application using a “glue” material to aid the coating process.

Each

approach uses gold in a +3 oxidation state, typically gold (III) chloride hydrate or gold
(III) acetate, and a reducing agent, such as sodium borohydride, sodium citrate, or oleyl
amine.

The reducing agent reduces gold (III) to metallic gold (0), starting with a

nucleation step followed by deposition and growth on the iron oxide NP to become the
shell.3,4 As mentioned previously, coating iron oxide NPs with gold imparts adequate
biocompatibility to the resultant NPs and allows for flexible NP functionalization through
reactions with sulfhydryl (-SH) compounds. Another common functionalization method
includes the use of amines, as discussed by Grabar et al.5 in their report on 2D arrays of
colloidal gold NPs for surface-enhanced Raman scattering. The ready coating by thiols
and amines is due to the prominent interaction between amino or sulfhydryl groups and
gold. Leff et al.6 first synthesized and characterized amine-coated gold NPs in the 90s,
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and they concluded that the interaction between amino and gold is weakly covalent. This
is unlike the thiol-capped gold NPs first synthesized by Brust et al.,7 who described the
sulfhydryl and gold interaction as covalent. More specifically, the interaction between
sulfhydryl and gold has been explored at the nanoscale since the discovery of
spontaneous assembly of alkanethiols on noble metals.8 A recent review by Häkkinen9
describes the interaction as: “the sp3-type hybridization of sulfur, with two of the hybrid
orbitals making covalent bonds to the Au(6s) electrons, as well as the important
contributions from Au(d) electrons”.
Prior to gold coating, the magnetic iron oxide core must be synthesized. Methods
for this are described in Chapter 1.

Magnetic NPs can be made of a variety of

materials,10 including pure iron, cobalt, and nickel, but for the Fe@Au NPs of this work
the core is made from iron oxide. Iron oxide NPs consist primarily of magnetite (Fe3O4)
or its oxidized form maghemite (γ-Fe2O3). Recent reviews on Fe@Au NPs1,11 discuss
advances in the synthesis of Fe@Au NPs and claim the core for the majority of Fe@Au
NPs described in the literature consist of Fe3O4, although γ-Fe2O3 is used as well.12 The
process to coat γ-Fe2O3 is very similar to that of Fe3O4. For example, Siurdyba et al.13
used a short amino-terminated linker to coat a γ-Fe2O3 core, followed by gold nanoseed
capture strategy and then reduced gold to form a shell, which is quite similar to work
described later in this chapter. The following subsection reviews methods of preparation
of iron oxide NPs having Fe3O4 cores.
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a. Direct Aqueous
Fe3O4

Reducing Agent
HAuCl4, H2O

Iron oxide NP

Fe@Au NP

b. Direct Organic (Thermal Decomposition)
Reducing Agent
Gold (III) acetate
High temperature

Fe3O4

Fe3O4
Desorption

Adsorption
Au (III)

Fe3O4
Iron oxide NP

Fe@Au NP

c. Indirect
Fe3O4
Iron oxide NP

"Glue"

Gold Nanoseeds

Fe@APTMS
Reducing Agent
HAuCl4
Fe@Au NP

Scheme 2.1. Synthetic routes to Fe@Au NPs. a. Direct aqueous method uses reducing
agents such as sodium borohydride, glucose, sodium citrate, and ascorbic acid. b. Direct
organic method uses reducing agents such as oleyl amine and 1,2-diols. Adapted from J.
Chem. Commun. 2016, 52, 7528-7540. Copyright 2016 The Royal Society of Chemistry.
c. Indirect method, where the “glue” coating can be added in an aqueous or organic
solvent, and the shell formation can use either direct coating method. This “glue” is often
an
amine-terminated
molecule,
such
as
(3-aminopropyl)trimethoxysilane,
polyphosphazene, or polyethyleneimine. Adapted with permission from ACS Appl.
Mater. Interfaces 2013, 5, 4586-4591. Copyright 2013 American Chemical Society.
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The most common and simplest method for direct aqueous Fe@Au NP synthesis
involves iron oxide NPs that are gold coated by reaction in the presence of Au (III) and
sodium citrate as both a reducing agent and capping agent, as seen in Scheme 2.1a. As
the Fe@Au NPs are formed, they are immediately coated with sodium citrate, preventing
aggregation. Other reducing agents can be used, such as sodium borohydride addition
directly in solution followed by 3-mercaptopropionic acid capping 14 or delivery of
sodium borohydride via a micelle if microemulsion method is used,15 glucose followed
by chitosan coating,16 or ascorbic acid, which acts as both a reducing and capping
agent.17
One indirect method for gold coating is to use a seeding method that tethers gold
nanoseeds, which are GNPs with a diameter of 2-3 nm, to the iron oxide core prior to
bulk gold deposition, as seen in Scheme 2.1c. Seeding creates a point of nucleation for
the gold deposition to form the shell. An iron oxide core can be functionalized with (3aminopropyl)trimethoxysilane (APTMS) to give Fe3O4@APTMS. Simple mixing of
Fe3O4@APTMS with gold nanoseeds then enhances nanoseed attachment due to the
strong interaction between the amino moiety and gold.18,19 In addition, a thiol moiety can
be used for gold nanoseed attachment. Researchers have shown greater stability of
molecules bound to gold NPs using multiple thiol anchor points. The Mirkin group first
explored attachment of a cyclic dithiane-steroid linker to attach DNA onto GNPs.20
Unlike monothiol moieties that the group studied (Figure 2.2a), the dithiane approach
(Figure 2.2b) showed decreased susceptibility to displacement using dithiothreitol (DTT),
a common reagent used for cleaving the gold-thiol bond. Expanding this concept, the
Mirkin group developed an oligonucleotide with three thiol groups attached via an acetal
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backbone linker (Figure 2.2c),21 which had even greater stability toward displacement via
DTT. These syntheses provide robust attachment, but are quite complicated. Both
syntheses required multiple steps for DNA derivatization for attachment of the thiol
motifs. Sharma et al.22 performed a one-step derivatization of DNA for attachment to
gold nanoparticles (Figure 2.2d). They reacted amine-modified oligonucleotides with
carbon disulfide (CS2), which formed a dithiocarbamate in situ, followed by incubation
with gold nanoseeds. This created DNA-modified, coated gold nanoparticles using a
bidentate attachment, which showed increased robustness toward DTT in comparison to
ligands with monodentate attachment. After only 3 minutes of incubation with DTT, the
monodentate DNA-gold (Figure 2.1e) began to aggregate, as seen in the UV-Vis,
whereas after 1 hour the bidentate DNA-gold was still intact.
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Figure 2.2. DNA modified ligands attached via (a, e) monothiol, (b) dithiol, (c)
trithiol, or (d) dithiocarbamate. Adapted from the following sources: Bioconjugate
Chem. 2000, 11, 289-291. Copyright 2000 American Chemical Society. Nucleic
Acids Res. 2002, 30, 1558-1562. Copyright 2002, Oxford University Press. Chem.
Commun. 2008, 2140. Copyright 2008, Royal Society of Chemistry.

Another common Fe@Au NP synthesis uses high temperatures and organic
Wang et al. 23 first utilized a thermal

solvents to prepare hydrophobic NPs.

decomposition method to form such hydrophobic Fe@Au NPs. In a high boiling solvent,
such as phenyl ether at 185 °C, organic soluble iron oxide NPs were added to gold (III)
acetate and oleyl amine, which acts as a mild reducing agent and capping agent, followed
33

by the addition of a 1,2-diol and oleic acid. As seen in Scheme 2.1b, the coated iron
oxide NPs are stripped of the coating before gold is reduced onto the surface. Oleyl
amine then caps the gold as it is deposited onto the iron oxide until the entire shell is
formed. The NPs were purified via centrifugation and resuspended in hexane in the
presence of oleic acid and oleyl amine. Alonso-Cristobal et al.24 explored the effects of
varying the iron oxide:gold (III) acetate ratio and reaction temperature with regards to the
gold shell thickness. They found that the ratio did not affect the thickness of the gold
shell; rather, a larger amount of gold (III) acetate led to homogeneous nucleation, which
created gold NPs rather than coat the iron oxide NPs. This is a key observation that has
importance for this thesis work, as discussed in a later chapter. The optimal ratio of iron
oxide:gold (III) acetate was 0.05 mmol:3.7 mmol for iron oxide NPs with a mean
diameter of 7.5 nm. They also showed that a reaction temperature between 190 °C and
210 °C did not influence the gold shell thickness, but between 230 °C and 270 °C showed
significant gold shell thickness, from 3 nm at lower temperatures to 10 nm at higher
temperatures.
Though many researchers claim success with a variety of methods, it remains
difficult to control deposition of gold onto iron NPs. This is due to the differences in
surface energy between iron oxide and gold11,25 that oftentimes lead to the undesired coformation of GNPs. GNPs are caused by autonucleation. They also aggregate once
formed, thus complicating methods of purification. Undesired GNPs can be minimized
through optimization of the ratio of iron oxide to gold, although too little gold precursor
can lead to incomplete coating and thus exposure of the iron oxide NP. Conditions need
to be carefully controlled in order to maximize complete gold coating without GNP

34

formation – this is the key challenge in the field. If GNPs are formed, though, one
method of separation from Fe@Au NPs is to use centrifugation to give monodispersed
Fe@Au NPs.23

2.2.

GOLD SEEDED IRON OXIDE NANOPARTICLES
We first sought to prepare Fe@Au NPs via gold seeding followed by a Au (III)

reduction approach to try to thwart the major problem of GNP formation faced in many
of the other methods. Our first idea to make gold-coated iron oxide nanoparticles was
based on some previous work done by Dr. Stephanie Mattingly in our lab.26 In this work,
she sought to modify the iron oxide nanoparticles by reaction with CS2 to yield xanthate
functionality that would then serve as the “glue” for subsequent small molecule
attachment (Scheme 2.2b). Xanthates are typically formed when organic alcohols in base
react with carbon disulfide followed by alkylation (Scheme 2.2a). Mattingly investigated
functionalization of the oxides on the surface of iron oxide nanoparticles by reaction with
excess carbon disulfide.

Ultimately, this work was unsuccessful but, upon further

research, we discovered related modifications to iron oxide NPs using CS2 that have been
reported and showed promise. 27 Instead of reacting naked iron oxide with CS2 to form a
xanthate, Lopes et al. functionalized iron oxide NPs with terminal primary amines that
then were reacted with CS2 to form dithiocarbamates (Scheme 2.2c, step 1).
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Scheme 2.2. a. Traditional xanthate ester formation. b. Ferric xanthate
variation. c. Dithiocarbamate formation (1) with subsequent gold seeding (2).
Lopes et al. used this approach (i.e., coatings with a siloxydithiocarbamate) to
scavenge colloid gold from an aqueous solution for purposes of water purification
(Scheme 2.2c, step 2). The reacted solution was then exposed to an external permanent
magnet, and the water was purified of the reacted gold nanoparticles.

In another

example, Montazerabadi et al.18 used a gold seeding method (Scheme 2.2c, step 2)
followed by Au (III) reduction to form Fe@Au NPs for MRI contrast. The following
describes this procedure, which was followed for synthesis of Fe@Au NPs via a seeding
method.
Following a modified procedure by Montazerabadi et al.,18 we used a short linker,
3-aminopropyl(triethoxysilane) (APTES), to coat the iron oxide NPs. Briefly, we reacted
excess APTES with iron oxide NPs that were prepared according to the method of
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Mikhaylova et al.28 The resultant reaction mixture was sonicated for 30 minutes. The
suspension was then rapidly stirred and heated at 60 °C in a sealed tube for 4 hours,
followed by magnetic separation and washing with methanol to remove excess APTES.
Comparison of the FT-IR spectrum of the starting “naked” iron oxide nanoparticles with
that of the APTES-reacted nanoparticles (Figure 2.3) suggests the NPs were modified as
desired, principally due to the appearance of C-H stretch (2929 cm-1 and 2840 cm-1), N-H
stretch (3358 cm-1), and characteristic Si-O-R stretching (1043 cm-1).

Figure 2.3. Comparison of FT-IR spectra of Fe3O4
NPs (top) and Fe3O4@APTES NPs (bottom).
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With APTES-coated iron oxide nanoparticles in hand, we next examined how to
attach the gold nanoseeds. In an effort to maximize attachment, we chose to follow a
modified synthesis provided by Sharma et al.,22 utilizing the bidentate chelation afforded
by reaction of the amine with CS2. After reacting Fe3O4@APTES in borate buffer with
saturated aqueous carbon disulfide, we added excess aqueous gold nanoseeds (2-3 nm).
Gold nanoseeds were provided as a gift by Dr. Martin O’Toole’s lab at the University of
Louisville (see method of preparation by Yong et al.29).

The solution was stirred

overnight, then purified via magnetic separation to give gold nanoseed-coated iron oxide
NPs (Fe@nAu).

Figure 2.4. STEM Image of Fe@APTES NPs
(light gray) decorated with gold nanoseeds (bright
spots) to form Fe@nAu NPs.

High-resolution transmission electron microscopy (HR-TEM) and scanning
transmission electron microscopy (STEM) imaging was performed on Fe@nAu NPs by

38

Dr. Jacek Jasinski. As seen in Figure 2.4, the Fe@APTES core is a lighter gray, and the
gold nanoseeds are bright spots. Each image showed aggregation, but this is common
when nanoparticles are dried and concentrated for imaging. Based on the HR-TEM
images, the average size of the iron oxide NPs was 10 ± 3 nm. In addition to imaging,
energy-dispersive X-ray spectroscopy (EDAX) was performed on a gold-seeded iron
oxide sample. This allowed precise analysis of the chemical composition of the sample,
which gave efficacy of coating. However, there was inconsistency in the coating. Dr.
Jasinski provided EDAX readings for 3 different samples, and examined different regions
within each sample. As seen in Figure 2.5, iron oxide is observed for regions 1 and 2, but
only region 1 showed characteristic gold signals. The inconsistent coating is seen not
only in multiple areas of the same sample, but also between different samples. This is
troublesome because we expected gold nanoseeds to cover the iron oxide core in its
entirety. Apparently only portions of the iron oxide core became coated with the gold
nanoseeds.

Despite this, we continued with the Fe@nAu, hoping the partial gold

nanoseed coverage would still provide enough nucleation sites to form the gold shell.
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Figure 2.5. EDAX of Fe@nAu, showing clear peaks for both iron oxide and gold
in region 1 (left) but only iron oxide in region 2 (right). Cu seen in both samples is
from the grid used for analysis.
Many researchers have reported gold shell formation after gold nanoseed
attachment (i.e., nucleation). Procedures utilize chloroauric acid with various reducing
agents to form the gold shell. Fe@nAu NPs were suspended in H2O containing HAuCl4,
followed by addition of reducing agent. We examined several procedures that utilized
sodium borohydride, 30 ascorbic acid,18 glucose, 31 and sodium citrate. 32 The product
obtained by each method was characterized via UV-Vis, dynamic light scattering (DLS),
and ζ-potential. UV-Vis allows the detection or absence of a surface plasmon resonance
(SPR) that is commonly seen with GNPs or a gold shell. The SPR peak is due to the
interaction of light with free surface electrons, which in turn oscillate. The electrons can
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release their energy in the form of heat or light. Colloidal GNPs give a characteristic
optical absorption peak around 520 nm.33 DLS measures the hydrodynamic radius of the
sample, and ζ-potential gives the charge of the NPs in a solution of water. Results are
seen in Table 2.1.

Reduction method

SPR band

DLS (nm)

ζ-potential (mV)

Ascorbic acid

None observed

2500

-6.0

Sodium citrate

None observed

3000

-42.0

Glucose

None observed

700, 200

+32.2

Sodium borohydride

None observed

2400

-15.7

Table 2.1. Analysis for synthesis of Fe@Au NPs via hydrophilic methods. All samples
were measured in 1 mL H2O at a concentration of 0.2 mM.
Unfortunately, none showed a characteristic SPR band representative of gold
coating. The lack of SPR peaks in any of the samples was disconcerting, and the
hydrodynamic diameters were far too large to be considered useful. The ζ-potentials are
relatively good. Because ζ-potential is a measure of the surface charge of the NPs, it is
best of the observed number is largely negative or largely positive.

This ensures

repulsion between NPs, discouraging aggregation. Despite the good ζ-potential, the
excessive hydrodynamic radii made it clear that this hydrophilic method approach was
problematic.

As mentioned previously, four common hydrophilic methods for gold

coating were attempted, and each method used freshly made Fe@nAu NPs. Each method
was performed only once, but the focus of this thesis work was to expand the use of a
thermally labile linker to Fe@Au NPs for drug delivery.
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In order to perform the

necessary experiments, a reproducible method for Fe@Au NPs was necessary. Thus,
instead of focusing on attempts to make the hydrophilic method work, we pursued a new
method needed for Fe@Au NP synthesis.
While attempting to coat iron oxide with gold via gold nanoseed nucleation and
reduction, we explored the possibility of capping the dithiocarbamate with methyl to
produce stable xanthate functionality that could be analyzed prior to gold nanoseed
capping. Mattingly et al.26 previously attempted methyl capping of xanthate-coated iron
oxide NPs with little success. Despite the failure to do so, a revised attempt to form
dithiocarbamates followed by methyl capping yielded success. We followed the previous
procedure for gold nanoseed capture, but added excess methyl iodide rather than gold
nanoseeds. Characteristic stretching of the C–N bond of NCS2Me at 1336 cm-1 and
asymmetric stretching of CS2 at 960 cm-1 provided evidence for methyl dithiocarbamate
formation.34 Whereas these results were promising, we did not pursue this approach
further due to success in ongoing accompanying work that led to our goal.

2.3.

CORE-SHELL IRON OXIDE-GOLD NANOPARTICLES
After failing to prepare Fe@Au NPs via a hydrophilic method, we chose to

attempt synthesis via the thermal decomposition method to yield hydrophobic Fe@Au
NPs. First, we synthesized oleyl amine-coated iron oxide NPs via a modified method
developed by Park et al.35 Briefly, we heated a biphasic water-ethanol/toluene solution
of iron (II) and iron (III) salts, as well as sodium oleate, at 75 °C for 4 hours to give
oleate-coated iron oxide NPs.

The NPs were pelleted from excess reagents via

centrifugation. HR-TEM, EDAX, and superconducting quantum interference device
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(SQUID) were performed, as seen in Figure 2.6, and agreed with the literature
characterizations.

Figure 2.6. Characterization of iron oxide NPs. a. HR-TEM image shows uniformly
sized NPs. b. SQUID analysis with field cooling (blue) and zero-field cooling (red); right
shows magnetic saturation and left shows blocking temperature determination. c. EDAX
analysis to show characteristic iron and oxygen peaks; Cu seen in the sample is from the
grid used for analysis.
HR-TEM revealed an average diameter of 5 ± 1 nm with good monodispersity.
EDAX gave characteristic peaks for iron oxide. The Cu peaks are due to the copper grid
used for analysis. SQUID measurements showed a magnetic saturation of 0.3 emu/g with
a narrow hysteresis loop at room temperature. This indicated superparamagnetic NPs
because a hysteresis loop should not be detected above the blocking temperature, in this
case 27 °C.18
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We then modified a synthesis procedure by Wang et al.23 to coat our newly
formed NPs with gold. Briefly, we combined iron oxide NPs with gold (III) acetate, oleic
acid, oleyl amine, and 1,2-tetradecanediol in phenyl ether under nitrogen at room
temperature. This solution was heated to 185 ± 5 °C for 90 minutes. After cooling to rt,
the NPs were pelleted via centrifugation. This procedure allowed for removal of excess
oleyl amine as well as any gold NPs formed during the synthesis. STEM, EDAX, UVVis and SQUID were performed on these NPs as seen in Figure 2.7.
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Figure 2.7. Fe@Au NP Characterization. STEM image of Fe@Au NPs showing good
monodispersity of Fe@Au NPs. Top right insert shows size of NP using STEM software.
Bottom right insert shows size distribution based on diameter of NPs in image.
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Figure 2.8. Fe@Au NP Characterization. a. UV-Vis reading that shows characteristic
SPR absorption around 540 nm. b. EDAX analysis to show characteristic iron, oxygen,
and gold peaks; C seen in the sample is from the grid used for analysis.
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Figure 2.9. Fe@Au NP Characterization, SQUID analysis. a. Field loops up to 7 T at
1.9 K and 300 K. b. Field-cooled (blue) and zero-ﬁeld-cooled (red) measurements
showing temperature dependence of magnetization under 10 mT.
STEM in Figure 2.7 revealed an average NP diameter of 7 ± 3 nm with relatively
good monodispersity, consistent with literature values.23 EDAX showed characteristic
peaks for both iron oxide and gold based on literature.24 UV-Vis analysis (Figure 2.8)
showed a characteristic SPR around 530 nm, consistent with literature values.23,24
SQUID measurements (Figure 2.9) showed a magnetic saturation of 6 emu/g with a
narrow hysteresis loop at room temperature. These results confirm the presence of
Fe@Au NPs, and we used this material in our subsequent experiments.

2.4.

DUAL NANOPARTICLE SYSTEM
For reasons that will become clear in a later chapter, we also synthesized a dual

NP system. As the name implies, the dual NP system consists of 2 different types of
NPs: gold NPs for attachment of thiol based moieties, such as our linker, and iron oxide
NPs for generation of local hyperthermia.
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Because the thermal decomposition approach worked to prepare Fe@Au NPs, we
chose a similar procedure sans the iron oxide core to give hydrophobic gold NPs (GNPs).
de la Presa et al.36 formed GNPs by reducing gold (III) acetate with oleylamine in phenyl
ether, oleic acid, and 1,2-tetradecanediol at elevated temperatures, which is the synthesis
we chose to follow. The resultant GNPs were characterized via DLS and SEM. DLS
revealed a hydrodynamic diameter of 224.3 ± 11.2 nm, whereas SEM revealed 5 ± 3.7
nm (Figure 2.10).

Figure 2.10. GNP characterization. SEM image that shows monodispersed GNPs
(bright spots) with minor aggregation (large bright spots). GNPs have an average
diameter of 5 ± 3.7 nm.
The second portion of our dual NP system is the iron oxide NPs. As previously
discussed, iron oxide NPs should be coated to avoid aggregation and prevent oxidation.
Instead of using a metallic coating as done previously, we chose to make our iron oxide
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NPs water-soluble by attaching polyethylene glycol (PEG). This procedure forms a
ferrofluid, which is a colloidal suspension of surfactant coated magnetic nanoparticles.
We followed a procedure from García-Jimeno and Estelrich37 that combined PEG 2000
with iron (II) and iron (III) salts at slightly elevated temperatures. This was followed by
addition of ammonium hydroxide to form water-soluble iron oxide NPs (MNPs), which
were washed repeatedly with water to remove excess PEG 2000. Characterizations
included ζ–potential, DLS and SEM. ζ–potential showed a surface charge of -22.4 ± 2.02
mV. DLS showed a hydrodynamic diameter of 716.2 ± 74.3 nm, whereas SEM gave a
diameter of 50 ± 16 nm (Figure 2.11).
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Figure 2.11. MNP characterization. SEM image that
shows good monodispersity (average diameter 50 ± 16
nm), though aggregation was seen when sample was dried
for analysis.
2.5.

CONCLUSION
NP preparation is well described in the literature, yet the process of coating iron

oxide NPs in a reproducible manner so as to exclude GNP formation is a major challenge.
Despite following literature procedures, we did not enjoy success in making Fe@Au NPs
via a gold seeding method, which led us to use a thermal decomposition method. The
characterizations showed data that was consistent with literature for Fe@Au NP
synthesis. HR-TEM images showed iron oxide cores around 5 nm, and STEM images
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showed monodispersed, well-defined NPs around 7 nm. These diameters matched quite
well with the diameters of the procedure we followed by Wang et al.23 The Fe@Au NPs
had a characteristic SPR peak for gold, and EDAX readings showing both iron oxide and
gold consistently, something we had not achieved previously.
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3.1.

INTRODUCTION
We selected a linker for the Fe@Au NP delivery system based on previous work

done in our lab. Knipp et al.1 designed, synthesized, and attached a linker to iron oxide
NPs for the same purpose, namely to respond to an external stimulus (AMF-generated
local hyperthermia) so that intramolecular cyclization of the linker releases a payload
(Scheme 3.1). The initial linker had 3 components: a terminal attachment point to load
onto a NP surface, a reactive portion that consisted of a nucleophilic amine (blue) and an
electrophilic carbonyl moiety (red), and a payload (green).

(AMF)

Scheme 3.1.
Thermally responsive linker that
undergoes intramolecular cyclization upon exposure to
AMF to release a payload; blue = nucleophilic element
(amine), red = carbonyl moiety, green = payload
Knipp et al.2 first explored different parameters for optimal linker design prior to loading
onto a surface (Figure 3.1).

An allyl moiety was chosen as the surrogate for the

attachment portion because it could easily be modified when needed yet remained inert
during evaluation of the cyclization parameters. The reactive portion consisted of a
nucleophlic amine and various electrophilic carbonyls, including ester (1), carbonate (2),
carbamate (3), and amide (4). In addition, the carbon chain length was varied between
the nucleophilic amine and the electrophilic carbonyl to assess the influence of ring size
formation on exposure to heat. The payload used for the studies was anthracene, which is
UV active and fluorescent and readily quantified using known methods.
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Figure 3.1. Cyclization precursors (R = 2-(9anthracenyl)ethyl). Ring size after intramolecular
cyclization given in parentheses. Adapted with
permission from Tetrahedron 2014, 70, 3422-3429.
Copyright 2014 Elsevier.
After synthesis, each linker was incubated at 55 °C in methanol for 24 hours. Aliquots
were taken at various times for analysis via HPLC to determine percent release. Ester 1.1
cyclized most readily, with nearly complete release of the anthracene alcohol group after
incubation for 24 hours. Thus, this linker design was chosen for application in a carbonyl
capture demonstration using a poly(dimethylsiloxane) (PDMS) microchannel.

The

attachment portion was modified to incorporate a triethoxysilane for covalent attachment
to the microchannel. The anthracene payload was replaced with an aminooxy moiety
capable of reacting with carbonyl analytes. To test the applicability of the system on a
surface, the siloxane-linker was attached to the microchannel, and then incubated with an
aqueous soluble fluorophore, fluorecin isothiocyanate (FITC), which was modified with a
short chain containing an aldehyde. 3

After rinsing to remove excess FITC, the
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microchannel was incubated at 60 °C for 30 minutes and nearly complete release of the
fluorophore was observed.
With this success, Knipp et al.1 used the aforementioned linker design for
attachment to iron oxide NPs once again using siloxane methodology, followed by AMF
exposure to induce local hyperthermia and intramolecular cyclization. Ester 1.3 (Figure
3.1) was the linker of choice because it was resistant to cyclization until heated (i.e.,
exposure to local hyperthermia). As previously discovered by Riedinger et al.,4 iron
oxide NPs exposed to an AMF provide enough thermal energy for azo bond cleavage, so
Knipp hypothesized the same energy could drive the intramolecular cyclization. Because
the temperature of the NP surface increases first, followed by the change in temperature
of the bulk solution,5 the area immediately near the NP is much hotter than the bulk
solution.

Anthracene was used as the payload for its ease of detection using a

fluorometer in a 2:1 water:acetonitrile solution. After 30 minutes of AMF exposure, a
large amount of payload was detected in the supernatant. Unfortunately, release from the
NP system without exposure to AMF was seen. The premature release was presumably
caused by ester hydrolysis facilitated by iron oxide acting as a Lewis acid. To mask the
oxide surface, the use of a silica shell, which reduced the Lewis acidity of the NPs, was
examined. The gem-dimethyl carbonate 5 (Figure 3.1) was chosen as the linker for the
silica-coated iron oxide NP studies because of its greater stability toward hydrolysis and
relatively low payload release during previous studies.
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Figure 3.2. Nucleophilic linker attached to silica-coated iron
oxide NPs (Fe@SiO2).
After the linker was attached to the silica-coated iron oxide NPs, both the Boc-protected
amine 6 and free amine 7 (Figure 3.2) NPs were exposed to an AMF. Release was
observed for 6, which was unexpected because the Boc protecting group makes the amine
less nucleophilic. More importantly, the Boc-protected amine is not able to cyclize
because cyclization would result in a quaternary amine, which is highly unlikely. For this
reason, a modified linker that lacked an amine and used a robust N-methyl carbamate
moiety was explored. Stronger carbamate functionality would reduce the amount of
undesired payload release but would release under forcing conditions when local
hyperthermia was generated upon exposure to AMF. Instead of relying on intramolecular
cyclization, the carbamate linker cleaved via pure hydrolysis. Almost 70% payload
release was observed after 8 5-minute pulses at 500 A, while less than 10% payload
release was observed at 37 °C. Knipp et al. concluded that the silica shell provided
sufficient hydrogen bonding for accelerated hydrolysis and/or Boc-deprotection of the
carbonate, as well as accelerated hydrolysis of the carbamate.

3.2.

AMINE LINKER
This thesis work aims to apply the intramolecular cyclization strategy described

above to NPs that are otherwise inert. Silica shells have numerous qualities appealing for

56

drug delivery, including controlled thickness of deposition onto an iron oxide core,6
covalent attachment of drugs or antibodies,7 and a variety of ways to coat the iron oxide
core with silica.8 While the silica shell is important to increase functionalization of the
iron oxide core, bare silica NPs are reactive both in vitro and in vivo, i.e. their silanol
group is negatively charged at physiological pH (~7.4) and interacts with red blood cells,
causing hemolysis.7, 9 Even after coating the silica shell, it was still reactive, as
demonstrated by Knipp et al. with ester and carbonate hydrolysis. We sought to use a
gold shell because gold is bioinert10 and is functionalized easily to form covalent bonds
with thiols.11 We planned our studies to use a mono-thiol because we felt in this case a
di- or tri-thiol was not necessary. The 7-membered ring formation was used because of
its stability at physiological temperatures with response to thermal stimuli at relatively
high temperatures. The payload portion of the linker utilized the aminooxy moiety for
facile attachment of fluorescent carbonyl containing compounds seen in Figure 3.3.
Core
Shell

Fe3O4
-------

Functionalization
Linker synthesis
with FL prior to
loading onto NPs
Carbonyl
functionality
Ring size
Result from 37 °C
incubation

Knipp et al.
Fe3O4
SiO2
Siloxane
condensation

Biladeau
Fe3O4
Au
Thiol
monolayer

4 steps

7 steps

10 steps

11 steps

Ester

Carbonate

Carbamate

Carbonate

5
Uncontrolled
hydrolysis

7
Amine-free
7
Uncontrolled
Limited
No uncontrolled
hydrolysis
hydrolysis
hydrolysis
AMFAMFResult from AMF Uncontrolled
Intramolecular
promoted
promoted
exposure
hydrolysis
cyclization
hydrolysis
hydrolysis
Table 3.1. Summary of improvements relative to Knipp et al.1
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Initially, boron-dipyrromethene (BODIPY) was the fluorophore used per
recommendation of collaborators.

BODIPY is often used in biochemistry for

conjugation of nucleotides, amino acids, and other low molecular weight ligands.12 It
was used in early studies because of its superior fluorescence that spans the visible
spectrum,

depending

on

the

modifications.

BODIPY

was

modified

with

aminoacetaldehyde to yield a carbonyl containing BODIPY-CHO (Figure 3.3a).
Ultimately, we found little success using this fluorophore because it was insoluble in
water, despite use of 2:1 water:acetonitrile as well as derivatization of the fluorophore to
aid in solubility. We also examined the anthracene fluorophore from the work of Knipp
et al. in initial proof of concept studies. Finally, water-soluble molecules were used later
in our studies, including lissamine rhodamine B (LRB), and fluorescin isothiocyanate
(FITC). All fluorophores were attached to the protected linker system (LS) via the click
oximation reaction depicted in Figure 3.3a. Lissamine rhodamine B combines the core of
rhodamine with the sulfonyl groups of lissamine, which can be used for functionalization.
In our case, a terminal sulfonyl chloride was used, and, following a procedure by Park
and Yousaf,13 1,4-dioxa-8-azaspiro[4.5]decane was attached followed by stirring with
acid to yield LRB-CHO (Figure 3.3b). Unfortunately, we had little success with LRB,
despite following the literature procedure carefully. Instead, a derivatized FITC was
used, which was synthesized previously in our lab. FITC itself does not contain a
carbonyl to react with our linker, so it was modified with a short chain that contained a
terminal amine, which reacted with the isothiocyanate, as well as a terminal acetal, which
is simply a masked carbonyl (Scheme 3.2).2
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Scheme 3.2. FITC-CHO synthesis. Step 1: 4-aminobutyraldehyde diethyl acetal reacts
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Et3N, CH2Cl2, 0 °C; c. Phthalimide, K2CO3, DMSO, 75 °C; d. Hydrazine monohydrate,
CH2Cl2:EtOH, 0 °C; e. MeCN, 55 0 °C, 43% over 5 steps; f. Boc2O, Et3N, CH2Cl2, 0 °C;
g. TBAF, THF, 0 °C, 98% over 2 steps; h. 1,1’-carbonyldiimidazole, (i-Pr)2NEt, CH2Cl2,
0 °C; i. N-(2-hydroxyethyl)phthalimide, DBU, MeCN, rt, 51% over 2 steps; j. N2H4•H2O,
CH2Cl2, 0 °C, 99%; Tr = CPh3, Boc = C(O)Ot-Bu, TBS = SiMe2t-Bu

The synthesis of the amine linker, protected LS1, is outlined in Scheme 3.3. Each
product was characterized by 1H NMR,
characterized by HRMS.

13

C NMR, and IR, with key intermediates

To install the amine moiety, commercially available 1,4-

butanediol 10 was mono-TBS protected and followed by mesylation using standard
protocols. Reaction with phthalimide under Gabriel reaction conditions followed by
hydrazinolysis gave primary amine 11. Initial syntheses were done on the milligram
scale but after optimization, the reactions were scaled up and performed on the gram
scale (e.g. Step a in Scheme 3.4 yielded 4.52 g of a monoprotected diol). Confirmation
of formation of 11 can be seen in the 1H NMR,
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13

C NMR, and IR. The phthalimide

(Scheme 3.4, step c) gives characteristic 1H NMR peaks in the aromatic region, but these
signals are no longer evident in amine 11 (Figure 3.5).a

13

C NMR shows peaks in the

aromatic region as well as the carbonyl carbon signal, but are no longer present after
hydrazinolysis (Figure 3.6). IR analysis shows a strong characteristic C=O stretch at
1707 cm-1 from the phthalimide group but is absent in 11 (Figure 3.7).

TMS

CDCl3

b
a

TMS

CDCl3

11
b

a

Figure 3.5. 1H NMR of TBS-protected phthalimide (top) and amine 11 (bottom).
Aromatic peaks indicative of phthalimide (blue box). Phthalimide protons
zoomed in (top) to show doublet of doublet. aSynthesis of amine 11 has been
reported by Krivickas et al. (JOC, 72, 8280)
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Figure 3.6. 13C NMR comparison of TBS-protected phthalimide (top) and 11 (bottom).
Aromatic peaks (120-140 ppm) and carbonyl peak at 168 ppm indicative of phthalimide.
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Figure 3.7. IR spectrum of TBS-protected phthalimide (black) with
characteristic C=O stretch at 1707 cm-1 that is absent in amine 11 (red).

64

Commercially available 1,3-dibromopropane was reacted with triphenylmethanethiol to
give the tritylprotected-thiol bromide 3. Bromide 12 was reacted with 11 then purified
via column chromatography to give the secondary amine 13. After purification, the yield
after 5 steps was 43%. Purified amine 13 was Boc protected, followed by deprotection of
the TBS group using fluoride-mediated desilylation. The purified product was reacted
with carbonyl diimidizole to give 14. Characterization using 1H NMR of crude 14
showed a downfield shift in alpha protons after transformation from a hydroxyl to an acyl
imidazole (Figure 3.8, proton a, c). In addition, the hydroxyl proton disappears while the
acyl imidazole protons are seen in the aromatic region (Figure 3.8, proton b, d). The
crude acyl imidazole was reacted with a previously synthesized phthalimide alcohol,14
followed by hydrazinolysis to reveal aminooxy 15. At this point, any molecule with a
carbonyl could be attached for delivery using this system. Characterization using 1H
NMR of crude 15 showed protons of the aminooxy as a broad singlet around 5.5 ppm in
addition to distinction of the ethylene protons a and b (Figure 3.9). This was used for
attachment of either anthracene aldehyde or FITC-CHO, followed by trityl deprotection15
to reveal the thiol for attachment to Fe@Au NPs.
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Figure 3.8. 1H NMR spectra of alcohol (top) and acyl imidazole 14 (bottom). Each
sample was dissolved in CDCl3 with TMS and spectra were taken on a 400 MHz NMR
machine.
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Figure 3.9. 1H NMR spectra of phthalimide (top) and aminooxy 15 (bottom). Each
sample was dissolved in CDCl3 with TMS and spectra were taken on a 400 MHz NMR
machine.
3.3.

AMINE-FREE LINKER
In anticipation of demonstrating that the mechanism of payload release will

proceed via intramolecular cyclization, we pursued synthesis of a control linker system
that lacked the amine moiety while retaining all other aspects. Without an amine moiety
in the connecting chain, no release of payload can be expected based on an
intramolecular cyclization.
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TrS
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N
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TrS

O

O

ONH2

18

Scheme 3.4. Synthesis of protected LS2 18 a. Triphenylmethanethiol, K2CO3,
EtOH:H2O, 90 °C; b. 1,1’-carbonyldiimidazole, (i-Pr)2NEt, CH2Cl2, 0 °C; c. N(2-hydroxyethyl)phthalimide, DBU, MeCN, rt, 54% over 3 steps; d. N2H4•H2O,
CH2Cl2, 0 °C, 98%.

The synthesis for the amine-free linker is outlined in Scheme 3.4. Each product was
characterized by 1H NMR, 13C NMR, and IR, with key intermediates were characterized
by HRMS.

Commercially available 6-bromo-1-hexanol 16 was reacted with

triphenylmethanethiol to give trityl protected thio-alcohol as described in the aminebased linker, followed by reaction with 1,1’-carbonyldiimidazole to give the acyl
imidazole intermediate 17. Characterization of both the alcohol and acyl imidazole
products via 1H NMR is seen in Figure 3.10 and via IR is seen in Figure 3.11. As seen
with LS1, the proton from the alcohol disappears and a downfield shift is seen in the
alpha protons. In addition, the characteristic OH stretch is seen for the alcohol and the
C=O stretch is seen with the acyl imidazole.

17 was reacted with a previously

synthesized phthalimide alcohol14 and purified via column chromatography. The yield
over 3 steps after purification was 54%. The phthalimide was cleaved via hydrazinolysis
to give aminooxy 18. Characterization using 1H NMR of crude 18 showed protons of the
aminooxy as a broad singlet around 5.5 ppm in addition to distinction of the ethylene
protons a and b (Figure 3.12). This was used for attachment of either the anthracene
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aldehyde or FITC-CHO, followed by trityl deprotection12 to reveal the thiol for
attachment to Fe@Au NPs. Spectral comparison of protected LS1 and protected LS2 is
seen in Figure 3.13.
TrS
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OH
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TMS
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TrS

c
17

d
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N

b

TMS

N

c
d

Figure 3.10. 1H NMR spectra of alcohol (top) and acyl imidazole 17 (bottom). Each
sample was dissolved in CDCl3 with TMS and spectra were taken on a 400 MHz NMR
machine.
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Figure 3.11. IR spectrum of alcohol (black) with characteristic OH stretch
at 3362 cm-1 that is absent in acyl imidazole 17 (red), but instead has a
characteristic C=O stretch at 1768 cm-1.
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Figure 3.12. 1H NMR spectra of phthalimide (top) and aminooxy 18 (bottom). Each
sample was dissolved in CDCl3 with TMS and spectra were taken on a 400 MHz NMR
machine.
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Figure 3.13. 1H NMR spectral comparison of 15 and 18.
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3.4.

SUMMARY

Our goal was to prepare a linker system that:
TASK 1: could be readily “loaded” with a carbonyl substrate (e.g, FL or drug)
TASK 2: could be readily attached to GNPs
TASK 3: is resistant to non-triggered hydrolysis
TASK 4: responds to local hyperthermia to release attached carbonyl substrate

The following features within the linker system address each task:

HS

O

H
N

O

O

ONH2

SOLUTION 1: -ONH2 methodology allows for facile “click” attachment of carbonyl
substrates.
SOLUTION 2: -SH functionality allows for strong binding to surface of GNPs as well as
Au shells.
SOLUTION 3: Carbonate functionality is more resistant to hydrolysis than ester
functionality. In addition, 7-membered ring formation (slow) was selected to discourage
unassisted intramolecular cyclization.
SOLUTION 4: The pendant amine reacts only when local heat available to power a 7ring intramolecular cyclization, which results in substrate cleavage.

As mentioned previously, researchers explored the idea of thermally responsive linkers
with either azo or retro-DA functionality. These applications were attached to iron oxide
NPs and were successful in externally triggered payload release. The use of linkers that
clearly utilize organic reactions for payload release (i.e. azo decomposition, retro-DA
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reactions) is limited, so we sought to extend AMF technology to a more readily applied
release mechanism of intramolecular cyclization in an effort to expand this type of drug
delivery system. Use of a gold shell allows a quick and facile covalent bond between the
gold and the thiol functionality without the use of heat or vacuum as seen previously with
a silica shell. In addition, gold is inert, meaning it would not have interaction with the
linker other than initial attachment so undesired payload release would be minimal. For
these reasons, modifications were made for attachment to a gold shell and for
incorporation of a water-soluble fluorophore that would mimic release in vitro and in
vivo.
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4.1.

INTRODUCTION
Our amine linker attached to Fe@Au NPs is designed to cyclize in response to

local hyperthermia that can be generated upon exposure to an alternating magnetic field
(AMF). AMF is an effective method to create local hyperthermia when using magnetic
NPs, as described in Chapter 1. The amount of heat generated by the NPs in watts per
gram of iron (W/gFe) is denoted as the specific absorption rate (SAR). This can vary
when the machine is “on” because it is not only based on NP morphology, but is also
determined by the settings of the instrument, mainly power (W), current frequency (Hz),
and current amplitude (A). The current is the flow of electrons, and the electron flow acts
as a wave with variances in frequency and amplitude, as illustrated in Figure 4.1.

1 cycle

1 cycle

1 cycle

Amplitude

Point of current
alterna.on
Figure 4.1. Electrons behave as waves in a current. The frequency is the number of
cycles completed per unit time (blue). The amplitude is the maximum height of the wave
from its start point (red). An alternating current has positive voltage (above gray line)
and negative voltage (below gray line).
An electrical current running tough coils generates a magnetic field, as seen in
Figure 4.2.

In the case of an AMF, the current alternates direction based on the

frequency, which in turn alternates the direction of the magnetic field.
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Figure 4.2. Magnetic field generation. When current flows
through the coil (black), a magnetic field (green) is generated
in the direction. In this example, the current flows in through
the bottom of the coil and out through the top of the coil, and
the magnetic field direction is indicated by the arrows.
Heat generation, or SAR, is dependent partially on the magnetic field strength (kA
m-1) and partially on frequency (Hz).

Guardia et al.i explored both magnetic field

strength and frequency as it relates to SAR.

For magnetic nanocubes, SAR varied

linearly with the square of the strength of the magnetic field (Figure 4.3a), and SAR
varied linearly with the frequency of the current (Figure 4.3b). In terms of AMF settings,
this means a larger amplitude and/or frequency of current leads to larger heat dissipation,
or local hyperthermia.

77

Figure 4.3. a. At constant magnetic field strength (solid: 14 kAm1
, open: 18 kAm-1), SAR (W/gFe) readings correlate in a direct
linear fashion with frequency (kHz). b. At constant frequency
(700 kHz), SAR (W/gFe) readings correlate in a direct linear
fashion with the square of the magnetic field strength (kAm-1).
Adapted with permission from ACS Nano 2012, 6, 3080-3091.
Copyright 2012 American Chemical Society.
Generating local hyperthermia for cancer therapy is an area of great interest.
However, setting AMF parameters too high can lead to thermal ablation rather than local
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hyperthermia, so settings must be carefully regulated for in vivo treatment. In 1984,
Atkinson et al.ii implanted thermoseeds in healthy volunteers and concluded tolerance up
to 35.8 Aturns m-1 at a frequency of 13.56 MHz for 1 hour. Safety limits from this study
led to the “Brezovich criterion”, an equation where the product of the amplitude and
frequency should not exceed 4.5 x 108 Am-1s-1.iii Various in vivo testings have shown
adherence to this criterion, as seen in Table 4.1.
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Magnetic
field
strength
(kA/m);
Frequency
(kHz)
< 4;
50

Nanomaterial

NP
concentrati
on

CoPd rods

2-18;
100

SPIONs with
aminosilanetype shell
SPIONs with
aminosilanetype shell

1 cm apart 60 min
throughout
tumor
112 mg/mL 120 min
120 mg/mL 60 min
;0.2 mL
mag
fluid/mL
tumor
112
60 min
mg/mL;
0.28
mL/cm3
tumor
5 nM
60 min

0-18;
100

2-15;
100

SPIONs with
aminosilanetype shell

7.2-13.5;
334.5
11.3;
332.5

Iron oxide NPs

1.98;
203

Silica-coated
iron oxide NPs

15;
500
None
given;
1950
1.98;
203

Iron oxide NPs

Iron oxide NPs

Zn/Co/Mn
doped Fe2O4
Gold-coated
iron oxide NPs

2.5 x 10-3
wt% and
2.5 x 10-2
wt%
7 mg/0.75
mL

Duration Adjuvant
therapy

Cancer
type

Year

Yes (rad)

Prostate

2003iva

Yes (rad)

Brain
Tumor

200320054b

No

Prostate

20054c

Yes (rad)

Recurrent 20114d
glioblastoma
multiforme
20134e

2-27.5
min

20134f

6x5
min
bursts
20-25 µg
10-60
Fe/mL
sec
None given 5 min

20154g

10 mg/mL

2017

4 x 15
min
bursts

20164h
20174i

Table 4.1. Examples of in vivo thermotherapy that adhere to the Brezovich criterion.
Light gray portion represents NPs with thermally labile linkers, and settings used for the
present thesis work are in blue. See Chapter 4, reference 4, for references to each work.
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Recent payload release studies via a thermally labile linker show relatively similar
AMF settings (Table 4.1, light gray). Adherence to the Brezovich criterion is crucial for
drug delivery that will rely on AMF exposure. Thus, we chose our AMF settings to be
similar to the recent given examples in literature (Table 4.1, blue).

4.2.

INITIAL STUDIES – ANTHRACENE
The setup of AMF for the following studies is seen in Figure 4.4. The machine is

an Ambrell® EasyHeat Induction Heating System 10.0 kW with a 5-turn coil for AMF
exposure.

The machine settings, such as current amperage and duration of AMF

exposure, can be adjusted, but the frequency is set at 203 kHz (Figure 4.4a, red box). The
bulk solution temperature is monitored using Neoptix NeoLink software, and the
computer is connected to the temperature monitor (Figure 4.4a, green box) with a fiber
optic probe (Figure 4.4a, yellow). The sample in an Eppendorf tube, surrounded by
ceramic paper (Ambrell) to prevent heat from the coils to influence the bulk temperature,
is placed on a plastic box at the center of the coils (Figure 4.4a, orange box; Figure 4.4b).
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a

b

Figure 4.4. AMF machine setup. a. Overall view. In the red box, settings such as
current amperage and duration could be adjusted. The frequency for this machine was set
to 203 kHz and could not be adjusted. In the green box, a computer uses Neoptix
NeoLink software and is connected to a temperature monitor (grey box) with a fiber optic
probe (yellow). The orange box contains the sample with the probe to monitor bulk
solution temperature placed in the middle of the coils. b. A closer view of the orange box
from a shows the sample in an Eppendorf tube surrounded by ceramic paper (Ambrell®,
0.06” thick) to prevent heat transfer from coils. Inset shows aerial view of sample setup.
Prior to loading LS1 (Scheme 4.1, 20) on Fe@Au NPs, we attached a fluorophore
via the aminooxy functionality. For initial studies, an anthracene-aldehyde 8 was used, as
previously studied in our lab.i Fluorophore 8 was loaded on protected LS1 15 to give
protected LS1-anthracene 19, which was characterized via 1H NMR, 13C NMR, and IR.
Figure 4.5 shows 19 as both E and Z isomers, as indicative of signals from protons a and
b.
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Figure 4.5. 1H NMR spectrum of protected LS1-anthracene 19. The chemical shift
differences between the E and Z isomer are seen in proton a and proton b.
Because the payload release weight is identical for both isomers, the geometry of the
isomer is trivial. The trityl and Boc protecting groups were simultaneously removed
following a literature procedure to give LS1-anthracene 20.i Briefly, 19 was dissolved in
1:1 TFA:CH2Cl2 at 0 °C, followed by addition of Et3SiH. The importance of Et3SiH for
the mechanism of trityl deprotection can be seen in Scheme 4.1.
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Scheme 4.1. Mechanism of trityl deprotection.

After TFA protonates the sulfur (Step 1), SN1 chemistry occurs to form a thiol and a
tertiary carbocation (Step 2). The hydride of Et3SiH reduces the carbocation to give
triphenylmethane and triethylsilyl trifluoroacetate (Step 3). The solution was stirred for
30 minutes, and upon completion was concentrated in vacuo to give 20 and was used
without further purification.

20 was not characterized via NMR to prevent dithiol

formation prior to loading onto NPs, but a clear decrease in Rf value indicated
completion. After concentration in vacuo, 20 was redispersed in CH2Cl2, added dropwise
to NPs in hexanes, and stirred rapidly for 4 hours. The ratio of linker to NPs was 0.04
mmol linker per 1 mg NPs.

This initial loading method was determined our

collaborators, who also work in the nanoparticle field, Dr. Ralf Schirrmacher and Dr. Jun
Zhu at McGill University, Montreal, Canada. After 4 hours, the NPs were precipitated
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with EtOH, purified via centrifugation, and dried in vacuo to give Fe@Au@LS1anthracene NPs (Scheme 4.1, 21).
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Scheme 4.2. Synthesis of Fe@Au-LS1-anthracene (5). a. CH2Cl2, rt, 16
h, 99%; b. Et3SiH, 1:1 TFA:CH2Cl2, 0.5 h; c. CH2Cl2, rt, 16 h.
The loaded NPs then were dispersed in 1 mL of a 2:1 water:acetonitrile in a cuvette,
followed by exposure to an AMF at 500 A for 15 minutes. After exposure, the NPs were
separated via a strong magnet (N52 neodymium 1” magnetic cube, Applied Magnets,
Texas) and the supernatant was analyzed via matrix assisted laser desorption ionizationtime of flight (MALDI-TOF). When detecting a peak of interest in MALDI, it is possible
for the molecule to be protonated (mass + 1), sodiated (mass + 23), or potassiated (mass
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+ 39). Thus, masses for each of these versions were calculated and then inspected during
analyses.

Figure 4.6. MALDI-TOF spectrum of supernatant obtained from
Fe@Au@LS1-anthracene experiment after exposure to AMF at 500 A
for 15 minutes. The theoretical m/z for the protonated “payload”
fragment corresponds to the found m/z value of 279.22, confirming
payload release. The signal at 242.47 corresponds to a peak from the
matrix 2,5-DHB.
As seen in Figure 4.6, the signal for the protonated “payload” fragment [22]+ is observed
at a m/z of 279.22. This data strongly supports the notion that 22 is released as a result of
the AMF exposure, but the actual mechanism of cleavage must still be verified. To
investigate our intramolecular cyclization hypothesis, we loaded Fe@Au NPs with our
amine-free linker, LS2-anthracene (24). The method in which the NPs were reacted with
the linker thiol was kept the same. Click-chemistry oximation of anthracene-aldehyde 8
onto protected LS2 18 delivered protected LS2-anthracene 23. Protected LS2-anthracene
23 was characterized via 1H NMR,

13

C NMR, and IR. Trityl deprotection gave LS2-

anthracene 24, which was used without further purification. 24 was not characterized via
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NMR to prevent dithiol formation prior to loading onto NPs, but a clear decrease in Rf
value indicated completion. After concentration in vacuo, 24 was redispersed in CH2Cl2,
added dropwise to NPs in hexanes, and stirred rapidly for 4 hours. The ratio of linker to
NPs was 0.04 mmol linker per 1 mg NPs. After 4 hours, the NPs were precipitated with
EtOH, purified via centrifugation, and dried in vacuo to give Fe@Au@LS2-anthracene
NPs (Scheme 4.2, 25). The NPs were dispersed in 1 mL of a 2:1 water:acetonitrile
cuvette, followed by exposure to an AMF at 500 A for 15 minutes. After exposure, the
NPs were separated via a strong magnet and the supernatant was analyzed via MALDITOF. As seen in Figure 4.7, the m/z signal of 279.22 for the protonated “payload”
fragment [22]+ expected in this case was not seen, indicating payload release had not
occurred.
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Scheme 4.3. Synthesis of Fe@Au-LS2-anthracene (9). a. CH2Cl2, rt, 16
h, 99%; b. Et3SiH, 1:1 TFA:CH2Cl2, 0.5 h; c. CH2Cl2, rt, 16 h.
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Figure 4.7. MALDI-TOF spectrum of supernatant obtained from
Fe@Au@LS2-anthracene experiment after exposure to AMF at 500 A
for 15 minutes. The theoretical m/z of 279.22 for protonated “payload”
fragment is not seen in the spectrum, nor is the theoretical m/z for the
sodiated or potassiated “payload” fragment. This led us to believe a
payload was not released. The signal at 205.22 corresponds to a peak
from the matrix 2,5-DHB.
While this result was what we expected, it is not conclusive (e.g., lack of a signal may be
due to other factors). It is possible that, despite following the same preparation, LS2anthracene 24 was not loaded onto the Fe@Au NPs as efficiently. We therefore sought a
method to chemically cleave the payload from the Fe@Au-LS2-anthracene NPs 25 to
demonstrate that the system, in fact, did load LS2-anthracene 24, but simply did not
release it upon exposure to an AMF (Figure 4.9). To cleave carbonate functionality,
forcing conditions, such as strong base, are usually required. Concellón and del Solari
used 50% w/w aqueous NaOH at room temperature to hydrolyze a chiral carbonate in
MeOH to afford enantiopure diols. We tested protected LS2-anthracene 23 prior to trityl
deprotection and loading onto NPs following this procedure. Briefly, we added 50%
aqueous NaOH to protected LS2-anthracene 23 in methanol and monitored the reaction
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via TLC. The starting material was not consumed, even after 4 hours. Despite this, the
reaction was worked up, and analysis of the crude product via 1H NMR revealed no
carbonate cleavage. Subsequent experiments at an elevated temperature (i.e. 70 °C for 8
hours) did provide evidence for carbonate cleavage via TLC monitoring, but 1H NMR
analyses were not entirely clear. We next explored reducing the carbonate using lithium
aluminum hydride (LAH), a different method used by Concellón and del Solar for
carbonate cleavage (Figure 4.9).

O
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LAH

N
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+

H

a
HO
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N

Scheme 4.4. Protected LS2-anthracene cleavage using LAH. Ethylene protons that
showed signal shift are indicated by a and b.
LAH is a strong reducing agent that reacts with carbonate functionality at room
temperature (25 °C).7 1H NMR analyses of the reaction of 23 with LAH in THF at room
temperature for 1 hour showed peak shifts in the signals from the ethylene protons
between the carbonate and payload (Scheme 4.3), indicative of carbonate cleavage. This
led us to testing the linker on Fe@Au@LS2-anthracene 25 to determine whether or not
the NPs were initially loaded. After reaction of 25 with LAH at 25 °C for 1 hour, the
supernatant was analyzed via MALDI. The protonated payload release m/z was present,
which confirmed that 24 was indeed loaded onto the NPs. However, reaction of 25 with
LAH resulted in numerous byproducts as seen in MALDI.
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For cleaner analysis, instead of cleaving the carbonate to prove linker attachment,
we sought a method to cleave the gold-thiol bond to give the linker system plus payload
in its entirety (Figure 4.9). We chose the reducing agent, dithiothreitol (DTT), which is
used in both gold-thiol bond cleavage as well as in dithiol reduction.ii Modifying a
literature procedure initially disclosed by Storhoff et al., iii we incubated 10 mg of
Fe@Au@LS2-anthracene 25 with 400 µL of 0.1 M DTT for 2 hours, followed by
magnetic separation and supernatant analysis.

Figure 4.8. MALDI-TOF spectrum of supernatant obtained from Fe@Au@LS2anthracene experiment after incubation with DTT for 2 hours (no AMF application prior).
The theoretical m/z of 478.15 for potassiated LS2-anthracene corresponds to the found
m/z value of 478.14, confirming linker loading. The signal at 411.49 corresponds to a
peak from the matrix 2,5-DHB.

This was done without exposure of the NPs to an AMF prior to DTT cleavage to
determine if, in fact, 24 was loaded. MALDI-TOF analysis (Figure 4.8) showed a m/z
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peak at 478.14, corresponding to the mass of the entire linker 20 plus potassium (m/z =
478.15). This data confirmed loading of LS2-anthracene onto the Fe@Au NPs. The
previous negative results of payload release from AMF exposure of Fe@Au@LS2anthracene, followed by these results confirming LS2-anthracene 24 loading, proved our
hypothesis. The mechanism for release was not due to carbonate hydrolysis; rather,
intramolecular attack of the amine on the carbonate, powered by the local hyperthermia
after exposure to an AMF, is a reasonable action to expect for release of anthracene
fragment 22 from LS1 versus LS2, where the attack is not possible.
3 DTT
O
S

O

Fe@Au

1

O

ON-FL

OH , 2 LAH

Figure 4.9. Cleavage strategies to confirm retention of
payload in 25. The first and second strategies to cleave the
carbonate bond using aq. NaOH and LAH, respectively,
gave analytically complicated results. Cleavage of the
gold-thiol bond using DTT, however, clearly showed the
linker in its entirety.
4.3.

WATER SOLUBLE STUDIES – FITC
Knowing that LS1 on Fe@Au NPs responded to AMF exposure, we sought to

examine the system using aqueous conditions to determine its release profile in
comparison to LS2. The amount of LS loaded onto NPs was modified slightly for these
studies. Previously synthesized Fe@Au-LS1-anthracene underwent thermogravimetic
analysis (TGA), an analytical method that monitors the mass of a substance as a function
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of temperature. The TGA results are seen in Figure 4.10, with calculations below. An
amount of 2.457 mg of Fe@Au-LS1-anthracene was heated from 25 °C to 800 °C over
30 minutes with a loss of 0.2015 mg (pink). Using the molecular weight of LS1anthracene (468.2 g/mol), the amount of mmol LS1-anthracene lost for 2.457 mg of
Fe@Au-LS1-anthracene was calculated as 4.3 x 10-4 mmol (Figure 4.10a).

By

subtracting the amount of LS1-anthracene lost from the total weight, the amount of
Fe@Au NPs could be calculated (Figure 4.10b). The amount of mmol LS loaded on each
mg NP was calculated as 1.9 x 10-4 mmol/mg (Figure 4.10c). Optimal loading amount of
linker to NP was to be 100 times excess as determined by consultation with a
collaborator, who works in the gold nanoparticle field, Mr. Kurtis James of the University
of Louisville, Kentucky. A total of 0.02 mmol LS per 1 mg Fe@Au NP was used. This
is half that of previous studies (0.04 mmol LS per 1 mg Fe@Au NP), meaning linker was
not wasted during loading.
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Figure 4.10. TGA analysis to determine weight of LS1-anthracene loaded onto Fe@Au
NPs. An amount of 2.457 mg Fe@Au-LS1-anthracene lost 0.2015 mg LS1-anthracene.
The total amount of LS1-anthracene loaded onto 1 mg Fe@Au NPs was calculated as 1.9
x 10-4 mmol.
Prior to NP loading, LS1 and LS2 required a water-soluble fluorophore, and, as
mentioned previously, we chose FITC-CHO. Synthesis of FITC-CHO 9 was described in
Scheme 3.4. The procedure for fluorophore loading and attachment to NPs is the same as
with anthracene aldehyde 8 but with FITC-CHO 9 instead (Scheme 4.4, 4.5). Briefly, 15
or 18 was dissolved in 9:1 CH2Cl2:MeOH followed by addition of FITC-CHO to give
crude protected LS1-FITC 26 or protected LS2-FITC 27. Characterization of 26 via 1H
NMR in CDCl3 (Figure 4.11, top) reveals a lack of –ONH2 protons, but the FITC-CHO is
not seen. This is because FITC-CHO is not soluble in CDCl3, but when 26 was dissolved
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in DMSO-d6 (Figure 4.11, bottom), it not only showed the fluorophore attached but also
showed E and Z isomers as indicated by the blue boxes. Protecting group removal with
TFA and Et3SiH revealed LS1-FITC 28 or LS2-FITC 29. After concentration in vacuo,
28 or 29 was redispersed in 9:1 CHCl3:MeOH and added to rapidly stirring Fe@Au NPs
dissolved in CHCl3. The mixture was allowed to stir overnight and concentrated in vacuo
to give Fe@Au-LS1-FITC NPs 30 and Fe@Au-LS2-FITC NPs 31. The NPs were washed
sequentially with EtOH, saturated sodium bicarbonate, and water, pelleting each time via
centrifugation before the next wash. Once loaded onto the NPs, Fe@Au-LS1-FITC NPs
30 were water soluble, but unexpectedly Fe@Au-LS2-FITC NPs 31 were not watersoluble, as seen in Figure 4.12. The key difference between the linkers is the secondary
amine. We surmise that its ability to hydrogen bond with solvent aids in the water
solubility of Fe@Au@LS1-FITC NPs 30. Fortunately, a common ligand to increase NP
water-solubility is polyethylene glycol (PEG) – the oxygen abundant polymer forms
hydrogen bonds with water. For that reason, we pursued incorporating PEG to increase
water solubility of our NPs.
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Figure 4.11. 1H NMR spectra of 26 in DMSO-d6. The protons from FITC-CHO are
indicated in green boxes. Signals between 9.0 and 10.2 ppm indicate excess FITC-CHO
in solution. As seen with the ethylene protons of protected LS1-anthracene 19, E and Z
isomers are seen (blue boxes).
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Figure 4.12. Dispersion of Fe@Au@LS1-FITC NPs
(left) and Fe@Au@LS2-FITC NPs (right) in 1X PBS
buffer (pH = 7.4) after sonication. Fe@Au@LS1FITC NPs are well dispersed indicated by the
homogenous color, but Fe@Au@LS2-FITC NPs
sediment at bottom of the vial.
For our NPs in particular, we used a PEG (MW 5000) modified with a terminal
thiol for attachment to our Fe@Au NPs.1 We explored a variety of ratios of linker to
PEG (Table 4.2) to maximize payload release while maintaining water solubility. That is,
the greater amount of LS attached, the greater amount of payload carried for release.
Nevertheless, an appropriate amount of PEG must be used to maintain water solubility.
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Ratio
(LS:PEG)
1:1
7:3
9:1
10:0

LS1-FITC

LS2-FITC

Soluble
Soluble
Soluble
Soluble

Soluble
Not Soluble
Not Soluble
Not Soluble

Table 4.2. Ratios of LS:PEG explored. Each ratio
used with LS1-FITC was soluble in 1X PBS,
whereas only 1:1 LS2-FITC:PEG was soluble in
1X PBS.
Following Carril et al.2 in their coating of Fe@Au NPs, we began with a 1:1
mixture of mmol linker: mmol PEG-SH. Preparation of the linker system for NP coating
remained the same, but prior to its addition, PEG-SH was added to the mixture. The
solvent medium changed from CH2Cl2 to CHCl3 to follow a literature prep.10 A 1:1
mixture of 28 or 29 and PEG-SH was dissolved in 9:1 CHCl3:MeOH and added to
rapidly stirring Fe@Au NPs dissolved in CHCl3.

The mixture was allowed to stir

overnight, concentrated in vacuo, redissolved in CHCl3, suspended in EtOH, and purified
via centrifugation. After centrifugation, water solubility was evaluated by adding water
to the NPs followed by sonication. Both Fe@Au-LS1-FITC-PEG NPs (Figure 4.14a) and
Fe@Au-LS2-FITC-PEG NPs (Figure 4.14b) were water-soluble, as seen in Figure 4.12.
We also explored linker:PEG ratios of 7:3, 9:1, and 10:0 for both linker systems (Table
4.2). Because Fe@Au@LS1-FITC NPs 30 were water-soluble without the addition of
PEG, each of the ratios was water-soluble as well, as expected. Surprisingly, the only
ratio that was water soluble for LS2-FITC:PEG was 1:1. Despite long sonication times to
aid in dispersion, none of the ratios that increased the linker to above 1:1 were watersoluble. Thus, we continued our studies with this ratio.
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Once the NP system was optimized, Fe@Au-LS1-FITC-PEG NPs 30 were
characterized via UV-vis spectroscopy, ζ-potential, DLS, and SEM. UV-vis showed a
characteristic surface plasmon resonance band at 531 nm, indicating the presence of gold.
The ζ-potential was 12.6 ± 0.212 mV. This is not surprising because both LS1-FITC and
PEG are neutral in water. The DLS reading was 229.5 ± 0 nm, but the particles show
relatively good monodispersity and have an average diameter of 23 ± 7 nm based on
SEM imaging (Figure 4.13).

Figure 4.13. Fe@Au-LS1-FITC-PEG NPs 30 characterization. SEM image shows
moderate monodispersity of NPs (bright spots) with some salts from washing (light gray
spots).
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Figure 4.14. a. Fe@Au-LS1-FITC NPs 30 and b. Fe@Au-LS2-FITC
NP 31, with optimal ratio of PEG to LS-FITC as 1:1.
The release profiles were evaluated for both Fe@Au@LS1-FITC-PEG NPs 30
and Fe@Au@LS2-FITC-PEG NPs 31. Prior to the studies, a calibration curve was
created to determine the amount of payload release, as seen in Figure 4.15. Though the
fit is not ideal, this calibration curve incorporates all concentration values seen in the
following experiment. The excitation and emission of FITC was chosen as 475 nm and
525 nm, respectively, based on maximum excitation and emission studies. These were
input into the software for single read mode. FITC has a relatively high fluorescence
quantum yield, that is “the fraction of the number of quanta absorbed by a molecule that
are emitted as fluorescence” is near 1.0.3 For this reason, FITC could be detected in the
picomolar range on the fluorometer. The settings on the AMF were maintained as in our
initial studies using the anthracene payload, 500 A and 203 kHz, but the exposure time
was different.
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Figure 4.15. FITC calibration curve to include concentration
values 17 pM to 15.63 mM. Concentrations were established
through serial dilutions of FITC dissolved in 1X PBS buffer
followed by fluorescence readings. Though R2 value is only
0.977, the large concentration range included the smaller percent
release from Fe@Au-LS2-FITC-PEG as well as the larger percent
release from Fe@Au-LS1-FITC-PEG and “100%” after DTT
incubation.
Our initial studies showed release after only 15 minutes, but we wanted use
exposure times similar to that of current testing in vivo. In order to track how much
payload was released over time, we chose to expose the NPs to four 15-minute AMF
bursts with fluorescence readings after each burst. We also chose to pellet the NPs as a
means to completely remove them from suspension so as not to interfere with the
readings. For the studies, 10 mg of Fe@Au-LS-FITC-PEG were placed in an Eppendorf
tube with 1 mL 1X PBS buffer (pH 7.4) and then sonicated to suspend. The Eppendorf
tube was placed at the center of the AMF coil, and a fiber optic temperature sensor was
placed in the solution to monitor bulk solution temperature. All data was recorded using
Neoptix NeoLink software. The NPs were exposed to 15 minutes of AMF (500 A, 203
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kHz), followed by centrifugation at 10K rpm for 5 minutes (Figure 4.16a).

The

supernatant was removed via pipette, added to a plastic cuvette with 2 mL fresh 1X PBS
buffer, and analyzed via a fluorometer.

The concentration of cleaved payload was

calculated based on the calibration curve. After each reading, the solution that was
analyzed was added back to the tube containing the NPs and resuspended via sonication
so that a cumulative measurement could be made. The total amount of fluorophore
loaded onto the NPs – 100% release – was measured after the 4th reading by addition of
400 µL of a 0.1 M solution of DTT, incubation at rt for 2 hours, centrifugation at 10K
rpm for 5 minutes, addition of the supernatant to the cuvette followed by a final reading
(Figure 4.16b). Each percent release was determined relative to the total to establish
percent released. The studies via AMF were performed on both Fe@Au-LS1-FITC-PEG
NPs 32 and Fe@Au-LS2-FITC-PEG NPs 33, and each linker system was done in
triplicate.
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Figure 4.16. a. Fe@Au-LS1-FITC-PEG NPs 32 were exposed to AMF for 15 minutes
then pelleted via centrifugation for fluorescence readings. This process was repeated a
total of four times. After the final reading, the NPs were incubated with DTT for 2 hours
then pelleted via centrifugation to give “100%” fluorescence reading. This entire process
was performed with Fe@Au-LS2-FITC-PEG NPs 33 as well. b. As exposure time to
AMF increased, the percent of payload release increased, as indicated by the darker
colors, with the darkest color (i.e. 100% release) seen after DTT incubation.
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Figure 4.17. Release profile for Fe@Au-LS1-FITC-PEG NPs 30 (red)
and Fe@Au-LS2-FITC-PEG NPs 31 (blue) with 10 mg NP system in 1
mL 1X PBS buffer (pH 7.4). Percent payload released after 4 15-minute
bursts of AMF exposure (500A, 203 kHz). The bar gives average release,
and the error bars display standard deviation (n = 3).
The release profile for both Fe@Au-LS1-FITC-PEG NPs 30 and Fe@Au-LS2FITC-PEG NPs 31 is seen in Figure 4.17. After the first 15-minute burst, almost 15% of
the payload for LS1 system was released into solution, followed by reaching a plateau of
~40% release after the next 3 bursts. As anticipated, after a total exposure time of 60
minutes, LS2 showed significantly less release than LS1 with only 10% release after 1
hour total exposure time. Starting at room temperature (average temperature of 25 °C),
the temperature of the bulk solution reached a maximum temperature of 33 °C, 34.3 °C,
32.5 °C, and 33.3 °C for the 1st through 4th 15-minute exposures, respectively. The bulk
temperature of solution with 1X PBS only had a maximum temperature of 32.1 °C after
15 minutes of exposure to AMF. Release profiles were also explored at physiological
temperature (37 °C) as well as 50 °C. After incubation of 10 mg Fe@Au-LS1-FITCPEG in 1X PBS buffer for 2 hours (no AMF) at either 37 °C or 50 °C, only 6.8 ± 1.4%
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and 8.4 ± 6.4% release was seen, respectively. These results suggest that bulk solution
temperature does not play a pivotal role in payload release, rather it is the temperature
generated at the surface of the NPs that contributes (i.e., actuates intramolecular
cyclization) to cause payload release.

The high temperature at the surface of the

nanoparticle is accompanied by a very fast drop in temperature farther from the surface
(i.e., 0-5 nm vs >5 nm), according to the findings by Riedinger et al.4
While these results were exciting and showed a new mechanism is operative for
the first time, the plateau at 40% release perplexed us. A 100% payload release can be
expected because the mechanism should not be hindered in some NPs versus others. We
postulated that perhaps the addition of the PEG coating was trapping the payload after
release from the linker. To explore this possibility, we performed the AMF studies with
Fe@Au-LS1-FITC-PEG NPs 30 by washing the NPs with 1X PBS buffer. That is, we
placed the first supernatant after AMF exposure into an empty cuvette, resuspended the
NPs in fresh 1X PBS via sonication followed by centrifugation. The supernatant was
removed and placed into the cuvette, and this process was repeated once more. This
method was performed after each 15-minute exposure to AMF to determine the noncumulative amount released after each burst.

After the 4th reading, the NPs were

incubated with 400 µL 0.1 M DTT for 2 h and washed as just described. Each release
profile was calculated based on the calibration curve. To make the results comparable to
the previous cumulative results, each concentration after exposure was added to the
previous results (e.g. concentration reading after 15 minutes was 2.72 pM and
concentration reading after 30 minutes was 0.93 pM meaning the total release at 30
minutes was 3.65 pM). The reading after DTT that represented 100% release added all
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readings together.

Overall, the percent release was similar to the readings without

washing. This disproved our hypothesis of the released fluorophore being trapped within
the PEG layer. The plateau observation remains to be explained.
We next thought to increase the amount of local hyperthermia generated from the
Fe@Au NPs. As stated previously, the maximum bulk temperature for each burst was no
higher than 35 °C, and the bulk temperature of 1X PBS buffer without NPs was 32 °C.
We thought it possible that the concentration of iron oxide might be too low to produce
the necessary thermal energy for intramolecular cyclization and payload release. This
could be overcome by either decreasing the amount of solvent with the same amount of
iron oxide or increasing the amount of iron oxide with the same amount of solvent. We
chose the latter and explored “spiking in” iron oxide NPs to cause the bulk solution to
heat to a greater extent, thus triggering more payload release. Our first attempt involved
combining 10 mg of Fe@Au-LS1-FITC-PEG NPs 30 in 1 mL 1X PBS buffer with 10 mg
iron oxide NPs, previously made for the gold nanoseed project. The cumulative release
method was reinstated, as the washing method was clearly no better. Analysis of the
supernatant showed release percentages similar to what we observed before. However,
we noted that in this experiment the Fe3O4 NPs were not water-soluble and thus were not
adequately suspended in solution. Rather, the added iron oxide NPs sank to the bottom
of the Eppendorf tube during AMF treatment, while Fe@Au-LS1-FITC-PEG NPs 30
remained suspended in solution. The bulk solution had an average temperature of 39 °C,
which was higher than the temperature seen with Fe@Au NPs.

Likely, the heat

necessary to power the intramolecular cyclization at a reasonable rate was not
concentrated near the linker system, which may explain why the release percentages were
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no better. To determine whether suspension of the iron oxide is truly necessary for
greater release, we added ~10 µL of commercial ferrofluid, EMG 304, FerroTec, into a
solution of Fe@Au-LS1-FITC-PEG NPs 30. The release profile was higher than that of
Fe@Au NPs alone, with a maximum of 57% release after 60 minutes total exposure time.
In addition, the temperature was significantly higher, with an average maximum bulk
temperature solution of 47 °C after 15 minutes, a temperature well above any previous
study we performed.

These promising results of increased percent payload release

prompted us to improve the heating delivery as a means to increase the percent payload
release. This ultimately led to the use of water-soluble iron oxide NPs suspended in
solution with LS1-FITC coated gold nanoparticles (GNP@LS1-FITC NPs).

4.4.

DUAL NANOPARTICLE OPTION
After finding more release and a higher bulk solution temperature with a greater

concentration of iron oxide NPs in solution, we chose to explore how to optimize payload
release with different concentrations of iron oxide added as part of a dual NP option. We
chose not to use Fe@Au NPs to circumvent any potential issues of variance between
linker on the gold coating versus the amount of iron oxide present at the core due to size
variance in iron oxide core diameter, but instead opted to use a dual NP system consisting
of gold NPs (GNPs) and water-soluble magnetic iron oxide NPs (MNPs), as seen in
Figure 4.23b. This approach provided a platform for linker attachment (GNPs) with
consistent variance in the amount of local hyperthermia generated (MNPs).

The

mechanism of substrate release was already established from previous studies, which
meant only LS1 needed testing. Because Fe@Au-LS1-FITC 30 was water soluble, PEG-
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SH was not necessary, and concentration of GNPs in solution could be decreased since
the theoretical amount of linker on 10 mgs of Fe@Au-LS1-FITC-PEG NPs 30 was about
the same amount on 5 mg of GNP@LS1-FITC NPs. In addition, we decreased the
amount of LS1-FITC used for loading, and determined that only 0.01 mmol LS1-FITC
per 1mg GNP was necessary. GNP@LS1-FITC NPs were characterized via ζ-potential,
DLS, and SEM. ζ-potential showed a surface charge of -20.6 ± 1.63 mV. DLS readings
gave an average hydrodynamic diameter of 226.8 ± 26.77 nm, and SEM also shows
aggregation of that size (Figure 4.18a). Each individual particle, though, was much
smaller, as seen in Figure 4.18b. The fluorescence release was at a lower concentration,
so the calibration curve maximum concentration value was decreased. A new calibration
curve is seen in Figure 4.19.
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a

b

Figure 4.18. SEM of GNP@LS1-FITC. a. Aggregation of NPs shows a
diameter of 158.5 nm, consistent with DLS measurements. b. Individual
NPs show a diameter of 23.57 nm.
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Figure 4.19. FITC calibration curve for dual NP system (5 mg
GNP@LS1-FITC with 5 mg, 10 mg, or 15 mg of MNP) to include
concentration values 17 pM to 1.37 mM. Concentrations were established
through serial dilutions of FITC dissolved in 1X PBS buffer followed by
fluorescence readings.
The dual NP system was tested under the same conditions as in previous studies
with AMF settings of 500 A (magnetic field strength of 1.98 kA/m) and 203 kHz, and
exposure to an AMF for four 15-minute bursts. Fluorescent readings were taken between
each burst followed by 100% release through DTT incubation.

Each experiment

contained a ratio of 5 mg of GNP@LS1-FITC NPs with either an equal, twice, or thrice
amount of MNP by weight. Each experiment was performed in triplicate, and the results
are seen in Figure 4.20.
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Figure 4.20. Release profile at 500 A for GNP@LS1-FITC NPs:MNP at
ratios of 1:1 (blue), 1:2 (red) and 1:3 (green), showing percent payload
release after 4 15-minute bursts of exposure to an AMF (500A, 203 kHz).
The 1:1 shows results similar to previous studies with Fe@Au.
Significantly more release is seen with both 1:2 and 1:3, almost twice that
of previous studies with Fe@Au. The bar gives average release, and the
error bars display standard deviation (n = 3).
The data show that suspending iron oxide NPs in solution together with the GNP@LS1FITC NPs provides the necessary heat on AMF pulsing for payload release to occur. A
significant effect is noted when the amount of MNPs were twice or thrice that of GNPs.
We also explored the release profile of the same dual NP system ratios at a lower
magnetic field strength (1.19 kA/m, or AMF setting of 300 A and 203 kHz). With the
lower magnetic field strength, we hypothesized that payload release would be less than
that at 500 A because not as much local hyperthermia would be generated. The dual NP
system was tested under the same conditions as in previous studies with exposure to an
AMF for 4 15-minute bursts with fluorescent readings taken between each burst followed
by 100% release through DTT incubation, but with an AMF setting of 300 A (magnetic
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field strength of 1.19 kA/m) and 203 kHz. Each experimental ratio was performed in
triplicate, and the results are seen in Figure 4.21.
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Figure 4.21. Release profile at 300 A for GNP@LS1-FITC NPs:MNP at
ratios of 1:1 (blue), 1:2 (red) and 1:3 (green), showing percent payload
release after 4 15-minute bursts of exposure to an AMF (300A, 203 kHz).
Release is drastically reduced for each ratio in comparison to release at
500 A, but percent release increases with a greater concentration of MNP.
The bar gives average release, and the error bars display standard
deviation (n = 3).
As expected, the percent release at 300 A is lower than the percent release at 500 A. This
data also shows that the AMF exposure is responsible for the release of the payload, and
its decrease substantially effected substrate release. With a lower magnetic field strength,
payload release to only 35% is seen. In addition, as seen with the experiments at 500 A,
an increased ratio of MNP to GNP@LS1-FITC NPs shows greater percent payload
release. Clearly, both the amount of MNP in solution, along with the AMF settings,
contributes to the overall percent payload release.
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Release profiles were also explored for each experimental ratio (i.e. GNP@ LS1FITC NPs with equal, twice, or thrice the amount of MNP) at physiological temperature
(37 °C).

Each ratio was incubated in 1X PBS buffer for 2 1-hour intervals at 37

°Cfollowed by centrifugation and analysis. The release profiles after 1 hour for 1:1, 1:2,
and 1:3 was 12%, 18%, and 24%, respectively. After the second hour of incubation, the
percent release for 1:1, 1:2, and 1:3 increased to 24%, 30%, and 41%, respectively.
These values are much larger than the values from Fe@Au NPs. The MNPs were coated
in PEG following a literature procedure, but the release profiles suggest the PEG
coverage is not complete. One possibility is that the increased hydrolysis found by Knipp
et al. is happening with the dual NP system at 37 °C, i.e. the iron oxide core is exposed
and, because of its Lewis acidity, increased hydrolysis of the carbonate bond. It is also
possible that an exposed iron oxide core, which is anionic in nature, leads to local
hyperbasicity upon exposure to an AMF for carbonate cleavage. This result suggests
controlling the amount added and quality of coating must be controlled.
The Sun group first explored the synthesis of dumbbell-like Au-Fe3O4 NPs.5
Briefly, the GNPs are synthesized, followed by epitaxial growth (i.e., “single crystalline
material grows on single-crystalline substrate”)6 of Fe3O4 onto GNPs, which allows for
two distinct surfaces onto which attachment can be made. The Sun group later used the
dumbbell-like NPs as a drug delivery system.7 A Her2-specific monoclonal antibody
Herceptin was attached onto the iron oxide and a modified cisplatin was attached onto the
gold with a short thiol terminated linker, as seen in Figure 4.22.
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Figure 4.22. Dumbbell-like NPs with Herceptin attached to iron oxide NP via a catechol
and cisplatin attached to gold via a thiol. Adapted figure with permission from Nano
Lett. 2005, 5, 379-382. Copyright 2005 American Chemical Society.
The functionalized NPs were incubated at 37 °C with Sk-Br3 cells (Her2-positive breast
cancer cells) and MCF-7 cells (Her2-negative breast cancer cells). As expected, the Her2
receptor NPs better targeted the Sk-Br3 cells as compared to the MCF-7 cells. In
addition, 70% modified cisplatin was released into solution at pH 6 after one hour
incubation at 37 °C. By using a “dual NP” system that attaches the NPs together,
distribution can be improved and both NPs arrive at the same intended destination. If the
dumbbell-like NPs were not attached, the 2nm and 8nm GNPs would largely be found in
the kidneys, whereas the larger iron oxide NPs would not.8
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Figure 4.23. Different NP systems with exposure to AMF for payload release. a. Coreshell Fe@Au NPs with coating of PEG (
) and linker in a ratio of 1:1. Upon
exposure to an AMF, the core creates local hyperthermia to induce intramolecular
cyclization (amine = , carbonate = ) and payload release (). b. Dual NP system with
GNP coated with LS1-FITC and MNP. Upon exposure to an AMF, the MNPs create
local hyperthermia to induce intramolecular cyclization and payload release from the
GNPs.
4.5.

CONCLUSION
This thesis work has established that an alternating magnetic field can be used to

cause substrate release from NP carriers (Figure 4.23). We have shown for the first time
that intramolecular cyclization of linkers attached to Fe@Au NPs can function as a
triggerable mechanism for delivery. The challenge of creating monodispersed, evenly
coated Fe@Au NPs with minimal contamination by pure GNPs is a substantial hurdle to
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using this NP system as a carrier. The Fe@Au NPs we prepared and characterized were
likely contaminated with substantial amounts of GNPs. Despite that, our Fe@Au NP
system clearly released payload (~40%) upon exposure to an AMF. The dual NP system
released payload at both a higher setting of 500 A – nearly complete release was seen –
and a lower setting of 300 A. The concentration of iron oxide greatly improved local
hyperthermia generation and can improve release efficiency. Because the premature
payload release is a common problem when designing drug delivery systems containing
Fe3O4, the carbonate moiety may not be ideal for further development. The carbonate
functionality proved not to withstand mild heating without payload release, as seen in the
dual NP system.

If this remained the case with pure Fe@Au NPs, carbamate

functionality would be the next option (Figure 4.24). The delivery system described in
this work is flexible and can accommodate such structural changes.
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Figure 4.24. Modification of (a) LS1 from carbonate to (b) carbamate as
indicated by the rectangle. Upon exposure to AMF, the carbamate will
cyclize, release the payload (right), and leave a cyclic urea on the NP (left).
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5.1.

GENERAL STATEMENT
Reagent grade solvents were used for extraction and flash chromatography.

Acetonitrile was dried by distillation from CaH2. All other commercial reagents were
used as received without additional purification.

The progress of reactions was

monitored by thin-layer chromatography (TLC) using pre-coated silica plates (EMD
Silica Gel 60 F254). Visualization was accomplished by staining plates with PMA (3%
phosphomolybdic acid/ethanol solution) or PAA stain (2.5% p-anisaldehyde acid/ethanol
solution). UV active compounds were visualized by UV light (254 nm). Silica gel 60
(230-400 mesh) was used for flash column chromatography.
recorded at 400 or 500 MHz, and

13

1

H NMR spectra were

C spectra were recorded at 100 or 125 MHz,

respectively, in the indicated solvents. The chemical shifts are reported in ppm values
relative to the solvent residual peak CDCl3 (7.26 ppm for 1H NMR and 77.23 ppm for 13C
NMR) or TMS (0.00 ppm for 1H NMR). Coupling constants are reported in hertz (Hz).
High-resolution mass spectra were obtained using a FT-ICR-MS system (LTQ FT,
Thermo Electron Corp.) housed at the Center for Regulatory and Environmental
Analytical Metabolomics (CREAM) Mass Spectrometry Facility, University of
Louisville. Fluorescent measurements were taken on a Perkin Elmer LS 55 fluorescence
spectrometer at an excitation wavelength of 475 nm and emission wavelength of 525 nm.
Fluorescent measurements were taken using a plastic VWR two-sided spectrophotometer
cell with a 10 mm light path.

Scanning electron microscopy (SEM), transmission

electron microscopy (TEM), and scanning transmission electron microscopy (STEM) was
used to analyze size distribution and morphology of fabricated nanoparticles at the Conn
Center for Renewable Energy Research, University of Louisville, Kentucky or at the
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Nanotechnology Core Facility, University of Louisville, Kentucky. For SEM and STEM,
hexane-based (Fe@Au and GNPs) or water-based (Fe@Au-LS1-FITC NPs, GNP@LS1FITC NPs, and MNPs) nanoparticle dispersions were prepared and drop-casted on
commercially available 200 mesh TEM support Cu grids coated with ultra thin carbon
films. After solvent evaporation, the samples were imaged on a 200 carbon/copper mesh
with a Zeiss Supra Scanning Electron Microscope at a voltage between 10 kV and 25 kV.
For TEM, water-based nanoparticle dispersions were prepared and drop-casted on
commercially available 300 mesh TEM support Cu grids coated with ultra thin carbon
films. After water evaporation, samples were transferred to and analyzed using a field
emission gun FEI Tecnaci F20 transmission electron microscope operating at the
accelerating voltage of 200 kV.

Energy Dispersive A-ray Analysis (EDAX) was

performed on the Zeiss SUPRA-FE-SEM (Peabody, MA) at 20 keV. Samples were
prepared on a carbon coated copper mesh grid with a working distance of 8 mm.
Thermogravimetric analysis (TGA) measurements were made on a TA Instruments HiRes TGA 2950 Thermogravimetric Analyzer using a Pt basket and maintaining a flow of
N2 gas through the oven. Each TGA experiment was run from 35 C to 800 C at a ramp
rate of 20 °C/min. UV/Vis readings were taken using a Varian Cary 50 Bio. DLS and ζpotential measurements were taken using a Malvern Zetasizer: Nano-Zs90.

All

measurements were taken using aqueous colloids of the nanoparticles in Millipore water.
The alternating magnetic field (AMF) was generated with a Ambrell EasyHeat L1 set at
either 499.6 amps or 300.2 A and 203 kHz using a 5-turn coil. MALDI-TOF analysis
was done on a Voyager DE-Pro MALDI-TOF instrument (PE Biosystems). Sample
preparation was provided by Bruker Guide to MALDI Sample Preparation. Briefly,
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sample solvent (30:70 v/v acetonitrile:0.1% TFA in water) was added to an equal amount
of sample in liquid medium after testing. The matrix solution was prepared by addition
of 20 mg/mL 2,5-dihydroxybenzoic acid (2,5-DHB) to sample solvent. This was added
to an equal amount of sample in sample solvent and mixed vigorously. 0.5 µL sample +
matrix was spotted onto a ground steel MALDI plate. For matrix reference, 0.5 µL
matrix solvent was spotted onto a ground steel MALDI plate as well. Spectra were
acquired in positive reflectron mode and calibration was achieved by using known peaks
from the 2,5-DHB matrix.
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5.2.

CHAPTER 2 EXPERIMENTAL PROCEDURES

5.2.1. Preparation of gold seeded iron oxide NPs
Preparation of Fe3O4@APTES
Moditying the literature procedure of Montazerabadi et al.,1 3aminopropyl(triethoxysilane) (300 µL, 1.28 mmol) was added to iron oxide NPs (157.5
mg, 0.68 mmol) and sonicated at rt for 30 minutes. This mixture was heated at 60 C for 4
h, followed by magnetic separation and washing with MeOH. The NPs were dried in
vacuo and characterized by FT-IR, which showed characteristic C-H stretch at 2929 cm-1
and 2840 cm-1, N-H stretch at 3358 cm-1, and Si-O-R stretch at 1043 cm-1 (Chapter 2,
Figure 2.3).

Preparation of Fe3O4@nAu
Modifying the literature procedure of Sharma et al.,2 CS2 (1.5 mL, 24.94 mmol)
was added to a suspension of Fe3O4@APTES (157.5 mg) in borate buffer (1.5 mL) and
stirred for 1 h at rt. To this solution was added gold nanoseeds (1.5 mL of 10mM soln)
and stirred rapidly overnight. The NPs were magnetically separated and rinsed with DI
water (5 x 1 mL) to give Fe3O4@nAu NPs. Fe3O4@nAu NPs were characterized by HRTEM and EDAX (Chapter 2, Figure 2.4 and Figure 2.5), which showed inconsistent
coating of gold nanoseeds onto the iron oxide core.

Preparation of Fe@Au by reduction with ascorbic acid
Modifying the literature procedure of Montazerabadi et al.,1 HAuCl4 (0.5 mL of
10 mM soln) was added to Fe3O4@nAu NPs (18 mg) in water (2 mL) and sonicated for
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30 mins at rt. To the suspension was added ascorbic acid (100 mg, 0.57 mmol) and
stirred vigorously for 2 h, followed by magnetic separation and washing with water until
supernatant was clear (2 x 5 mL) then resuspended in water (10 mL) to give Fe@Au
NPs. These NPs were characterized via UV-Vis, DLS, and ζ-potential. UV-Vis did not
show a SPR band, DLS revealed an average hydrodynamic diameter of 2500 nm, and ζpotential showed an average surface charge of -6.0 mV.

Preparation of Fe@Au by reduction with sodium citrate
Modifying the literature procedure of Hu et al.,3 HAuCl4 (0.5 mL of 10 mM
soln) was added to Fe3O4@nAu NPs (18 mg,) in water (200 mL) while stirring
vigorously then immediately heated to 100 °C and held there for 10 minutes. To this
solution was added sodium citrate (10 mL of 5 wt % soln) and stirred for another 20
minutes at 100 °C. Upon cooling, the NPs were magnetically separated and washed with
DI water (2 x 10 mL) then resuspended in water (10 mL) to give Fe@Au NPs. These
NPs were characterized via UV-Vis, DLS, and ζ-potential. UV-Vis did not show a SPR
band, DLS revealed an average hydrodynamic diameter of 3000 nm, and ζ-potential
showed an average surface charge of -42.0 mV.

Preparation of Fe@Au by reduction with glucose
Modifying the literature procedure of Mandal et al.,4 glucose (0.5 g, 2.77 mmol),
Fe3O4@nAu NPs (18 mg), and HAuCl4 (0.5 mL of 10 mM soln) were added together
and sonicated for 15 mins., then heated at 35-40 °C for 1 h. The NPs were magnetically
separated and washed with DI water (3 x 5 mL) then resuspended in water (10 mL) to

125

give Fe@Au NPs. These NPs were characterized via UV-Vis, DLS, and ζ-potential.
UV-Vis did not show a SPR band, DLS revealed a cluster of NPs with hydrodynamic
diameter of 700 and 200 nm, and ζ-potential showed an average surface charge of +32.2
mV.

Preparation of Fe@Au by reduction with sodium borohydride
Modifying the literature procedure of Rivas,5 sodium borohydride (10 mL of
0.6M soln) was added to Fe3O4@nAu NPs (18 mg), followed by addition of HAuCl4 (1
mL of 10mM soln) and stirred vigorously at rt for 5 h. The NPs were magnetically
separated and washed with DI water (5 mL) then resuspended in water (10 mL) to give
Fe@Au NPs. These NPs were characterized via UV-Vis, DLS, and ζ-potential. UV-Vis
did not show a SPR band, DLS revealed an average hydrodynamic diameter of 2400 nm,
and ζ-potential showed an average surface charge of -15.7 mV.

5.2.2. Fe@Au NPs
Modifying the literature procedure of Park et al.,6 FeCl3·6H2O (540.6 mg, 2
mmol), FeCl2·6H2O (198.8 mg, 1 mmol), and C18H33ONa (2.4 g, 8 mmol) were dissolved
in ethanol (6 mL), deoxygenated water (4.5 mL), and toluene (10.5 mL). This mixture
was heated at 74 °C for 4 h under nitrogen. The resulting black mixture was cooled to
room temperature and ethanol (50 mL) was added to precipitate the particles. The
mixture was centrifuged at 4000 rpm for 10 min at 4 °C to pellet. A clear, light orange
supernatant was decanted off and the residual black pellet was re-dispersed in hexane (5
mL) by vortexing. Redispersed particles were precipitated with ethanol (40 mL) then
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centrifuged at 4000 rpm for 10 min at 4 °C to pellet. Redispersal, precipitation, and
centrifugation were repeated two more times. The pelleted particles were redispersed in
hexane (40 mL) and undispersed residues removed by centrifugation at 4000 rpm for 5
min at 4 °C. The resulting black supernatant was decanted, and hexane removed in vacuo
to obtain nanoparticles in solid form. Nanoparticles were stored under nitrogen at rt until
further use. NPs were analyzed via HR-TEM, EDAX, and SQUID (Chapter 2, Figure
2.6). HR-TEM revealed an average diameter of 5 ± 1 nm with good monodispersity.
EDAX gave characteristic peaks for iron oxide. The Cu peaks are due to the copper grid
used for analysis. SQUID measurements showed a magnetic saturation of 0.3 emu/g with
no hysteresis loop at room temperature. This indicated superparamagnetic NPs because a
hysteresis loop should not be detected above the blocking temperature, in this case 27 °C.
Modifying the literature procedure of Wang et al.,7 a solution of as prepared iron
oxide NPs (16 mg, 0.07 mmol), gold (III) acetate (80 mg, 0.2 mmol), oleic acid (50 µL,
0.15 mmol), oleylamine (300 µL, 0.911 mmol), and 1,2-tetradecandiol (0.3 g, 1.3 mmol)
in phenyl ether (10 mL) under nitrogen was heated at 185 °C for 1.5 h. After cooling to
rt, EtOH (40 mL) was added to precipitate the core/shell NP.

The mixture was

centrifuged at 3000 rpm for 5 min and the supernatant was discarded.

The precipitate

was redissolved in hexane (5 mL), followed by addition of EtOH 40 mL). The mixture
was centrifuged at 3000 rpm for 10 min and the upper purple GNP solution was
discarded. This process was repeated 5 times. The core/shell NP was collected after
centrifuge and NP were stored in solid form under nitrogen at rt until further use. NPs
were characterized via STEM, EDAX, UV-Vis, and SQUID (Chapter 2, Figure 2.7,
Figure 2.8, Figure 2.9). STEM revealed an average NP diameter of 7 ± 3 nm with

127

relatively good monodispersity, consistent with literature values.2

EDAX showed

characteristic peaks for both iron oxide and gold based on literature. 2 UV-Vis analysis
showed a characteristic surface plasmon resonance around 530 nm, consistent with
literature values. 2 SQUID measurements showed a magnetic saturation of 6 emu/g with
no detectable hysteresis loop above the blocking temperature of 27 °C.

5.2.3. Gold NPs
Modifying the literature procedure of de la Presa et al,8 to a rb flask a solution of
gold (III) acetate (100 mg, 0.27 mmol) and 1,2-tetradecanediol (500 mg, 2.17 mmol) in
phenylether (30 mL) were added at rt. The solution was heated up to 80 °C under
nitrogen, then oleic acid (0.32 mL, 1.01 mmol) and oleylamine (0.34 mL, 1.03 mmol)
were added and heated to reflux (260 °C) for 30 minutes.

After cooling to room

temperature, the GNPs were precipitated by adding EtOH (40 mL) and pelleted via
centrifugation at 3000 rpm for 5 min and the supernatant was discarded. The precipitate
was redissolved in hexane (5 mL), followed by addition of EtOH (40 mL). The mixture
was centrifuged at 3000 rpm for 10 min and the supernatant was discarded. This was
done once more, and after the final removal of supernatant, the NPs were dried in vacuo
and stored in solid form under nitrogen at room temperature until further use. NPs were
characterized via DLS and SEM (Chapter 2, Figure 2.10). DLS revealed a hydrodynamic
diameter of 224.3 ± 11.2 nm, whereas SEM revealed 5 ± 3.7 nm.
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5.2.4. Water-soluble iron oxide NPs
Modifying the literature procedure of García-Jimeno and Estelrich,9 PEG 2K (6.0
g, 3 mmol) was dissolved in a rb flask containing water (5 mL) while stirring at 45 °C.
To this was added FeCl24H2O (0.16 g, 0.8 mmol) and FeCl36H2O (0.435 g, 1.6 mmol).
After dissolution, NH4OH (10 mL of a 0.75M solution) was added under vigorous
stirring and stirred a further 30 min. Upon cooling to rt, the MNPs were poured into a
beaker and placed on a neodymium magnet (N52 neodymium 1” magnetic cube, Applied
Magnets, Texas). The supernatant was decanted and the MNPs were washed four more
times with water. Water was added until the desired concentration was achieved and
sonicated for 12 minutes. NPs were characterized by ζ–potential, DLS and SEM (
Chapter 2, Figure 2.11). ζ–potential showed a surface charge of -22.4 ± 2.02 mV. DLS
showed a hydrodynamic diameter of 716.2 ± 74.3 nm, whereas SEM gave a diameter of
50 ± 16 nm.
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5.3.

CHAPTER 3 EXPERIMENTAL PROCEDURES

5.3.1. Amine Linker
HO

OTBS

4-((tert-Butyldimethylsilyl)oxy)butan-1-ol. A solution of TBSCl (6.00 g, 39.8 mmol) in
dry CH2Cl2 (100 mL) was added dropwise over 1 h to a solution of 1,4-butanediol (16.9
mL, 191 mmol) and Et3N (7.77 mL, 55.7 mmol) in dry CH2Cl2 (100 mL) at 0 °C. The
reaction mixture was stirred overnight at rt. The solvent was removed in vacuo and the
remaining oil was extracted with hexanes (4x) and the combined extractions were washed
twice with sat. NH4Cl, once with brine, and then dried over Na2SO4, filtered and
concentrated in vacuo to afford crude 4-((tert-butyldimethylsilyl)oxy)butan-1-ol (7.28 g,
89%) as a colorless oil.

This material was used in the next step without further

purification. Spectral characteristics agreed with published data.10 IR ν (cm-1) 3349; 1H
NMR (400 MHz, CDCl3) δ 0.07 (s, 6H), 0.90 (s, 9H), 1.60-1.69 (m, 2H), 2.86 (br s, 1H),
3.62-3.68 (m, 4H); 13C NMR (100 MHz, CDCl3) δ -5.4, 18.3, 25.9, 29.8, 30.1, 62.7, 63.4.
HRMS m/z cald [C10H25O2Si]+ 205.1618, observed 205.1618.

MsO

OTBS

4-((tert-Butyldimethylsilyl)oxy)butyl methanesulfonate.
(1.09

mL,

14.1

mmol)

was

added

to

a

Methanesulfonyl chloride

solution

of

crude

4-((tert-

butyldimethylsilyl)oxy)butan-1-ol (2.51 g, 12.3 mmol) and Et3N (2.59 mL, 18.4 mmol) in
dry CH2Cl2 (50 mL) at 0 °C and the reaction mixture was stirred for 2 h at 0 °C and
washed twice with sat. NH4Cl. The combined aqueous layers were extracted twice with
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CH2Cl2. The combined organic phases were washed once with brine and then dried over
Na2SO4, filtered and concentrated in vacuo to afford 4-((tert-butyldimethylsilyl)oxy)butyl
methanesulfonate (3.22 g, 93%) as an orange oil. This material was used without further
purification. IR ν (cm-1) 1173, 1426; 1H NMR (400 MHz, CDCl3) δ 0.05 (s, 6H), 0.89
(s, 9H), 1.63 (m, 2H), 1.84 (m, 2H), 3.00 (s, 3H), 3.65 (t, J = 6.0 Hz, 2H), 4.27 (t, J = 6.8
Hz, 2H); 13C NMR (100 MHz, CDCl3) δ -5.4, 18.3, 25.9, 28.6, 37.3, 62.2, 70.2.

O
N

OTBS

O
2-(4-((tert-Butyldimethylsilyl)oxy)butyl)-2,3-dihydro-1H-isoindole-1,3-dione.
Phthalimide

(3.19

g,

21.7

mmol)

was

added

to

a

solution

of

4-((tert-

butyldimethylsilyl)oxy)butyl methanesulfonate (3.22 g, 11.4 mmol) and K2CO3 (1.89 g,
13.7 mmol) in DMSO (40 mL). The solution was heated to 75 °C for 17 h. The reaction
was then cooled to rt and quenched with water. The aqueous solution was extracted with
EtOAc (4x) and the combined organic phases were washed with water (3x). The organic
phase was then washed with brine, dried over Na2SO4, filtered and concentrated in vacuo
to afford 2-(4-((tert-butyldimethylsilyl)oxy)butyl)-2,3-dihydro-1H- isoindole-1,3-dione
as white crystals, mp 188-190 °C, and was used without further purification. IR ν (cm-1)
1707; 1H NMR (400 MHz, CDCl3) δ 0.04 (s, 6H), 0.88 (s, 9H), 1.53-1.60 (m, 2H), 1.711.79 (m, 2H), 3.64 (t, J = 6.2 Hz, 2H), 3.72 (t, J = 7.2 Hz, 2H), 7.71 (dd, J = 3.0, 5.4 Hz,
2H), 7.84 (dd, J = 3.2, 5.2 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ -5.2, 18.5, 25.3, 26.2,
30.2, 38.0, 62.7, 123.3, 132.4, 134.0, 168.6.
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H 2N

OTBS
11

(4-Aminobutoxy)(tert-butyl)dimethylsilane (11). Hydrazine monohydrate (2.95 mL,
60.9 mmol) was added to a solution of crude 2-(4-((tert-butyldimethylsilyl)oxy)butyl)2,3- dihydro-1H-isoindole-1,3-dione (4.06 g, 12.2 mmol) in 2:1 CH2Cl2:EtOH (60 mL) at
0 °C. The reaction mixture was stirred overnight, allowing the reaction to come to rt. The
solution was diluted with CH2Cl2, the white precipitate was filtered, and the filter cake
was washed with ample CH2Cl2. The crude solution was concentrated in vacuo to afford
11 (2.37 g, 98% over 2 steps) as a light yellow oil, having spectral characteristics in
agreement with published data,11 and was used without further purification. IR ν (cm-1)
3024, 3058; 1H NMR (400 MHz, CDCl3) δ 0.06 (s, 6H), 0.89 (s, 9H), 1.60-1.67 (m, 2H),
1.79-1.87 (m, 2H), 3.01 (t, J = 7.2 Hz, 2H), 3.65 (t, J = 6.0 Hz);
CDCl3) δ -5.3, 18.2, 24.6, 25.9, 29.7, 39.9, 62.3.

13

C NMR (100 MHz,

HRMS m/z cald [C10H26NOSi]+

204.1778, observed 204.1779.

TrS

Br

12
(((3-Bromopropyl)sulfanyl)diphenylmethyl)benzene (12). K2CO3 (0.80 g, 5.8 mmol)
followed by 1,3-dibromopropane (2.67 mL, 26.6 mmol) was added to a solution of
triphenylmethanethiol (1.5 g, 5.4 mmol) in dry THF (27 mL) under N2. The reaction was
refluxed for 24 h before cooling to rt. The reaction solution was washed twice with water,
extracted twice with Et2O, washed with brine, dried over Na2SO4, filtered and
concentrated in vacuo. The excess 1,3-dibromopropane was removed by distillation to
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afford 12 (1.99 g, 92%) as white crystals, mp 85-86 °C, (lit 90-92 °C) having spectral
characteristics in agreement with published data.12 IR ν (cm-1) 660, 1254; 1H NMR (400
MHz, CDCl3) δ 1.78-1.85 (m, 2H), 2.33 (t, J = 7.0 Hz, 2H), 3.33 (t, J = 6.6 Hz, 2H),
7.20-7.31 (m, 9H), 7.41-7.43 (m, 6H);

13

C NMR (100 MHz, CDCl3) δ 30.5, 31.8, 32.5,

66.9, 126.9, 128.1, 129.8, 144.9.

TrS

H
N

OTBS
13

12,12,13,13-Tetramethyl-1,1,1-triphenyl-11-oxa-2-thia-6-aza-12-silatetradecane (13).
(((3-Bromopropyl)sulfanyl)diphenylmethyl)benzene (742 mg, 1.87 mmol) was added to a
solution of (4-aminobutoxy)(tert-butyl)dimethylsilane (950 g, 4.68 mmol) in MeCN (20
mL) and the reaction was heated to 55 °C for 24 h. After cooling to rt, the reaction was
quenched with sat. NaHCO3 and extracted three times with EtOAc. The combined
organic phases were washed with brine, dried over Na2SO4, filtered and concentrated in
vacuo. The crude material was purified by column chromatography (SiO2, 0:1 to 1:4,
MeOH:CH2Cl2with 1% NH4OH gradient) to give 13 (692 mg, 71%) as an orange oil. IR
ν (cm-1) 697, 3300; 1H NMR (400 MHz, CDCl3) δ 0.04 (s, 6H), 0.89 (s, 9H), 1.45-1.52
(m, 4H), 1.53-1.60 (m, 2H), 2.19 (t, J = 7.2 Hz, 2H), 2.52 (q, J = 7.2 Hz, 4H), 3.60 (t, J =
5.8 Hz, 2H), 7.17-7.28 (m, 9H), 7.40-7.42 (m, 6H); 13C NMR (100 MHz, CDCl3) δ -5.1,
18.5, 26.1, 26.7, 29.1, 29.9, 30.8, 49.0, 49.8, 63.2, 66.7, 126.7, 128.0, 129.7, 145.1.
HRMS m/z cald [C32H46NOSSi]+ 520.3064, observed 520.3060.

133

Boc
N

TrS
tert-Butyl

OTBS

N-(4((tert-butyldimethylsiyl)oxy)butyl)-N-(3-((triphenylmethyl)sufanyl)

propyl)carbamate. Boc2O (327 mg, 11.5 mmol) was added to a solution of 12,12,13,13tetramethyl-1,1,1-triphenyl-11-oxa-2-thia-6-aza-12-silatetradecane (710 mg, 1.37 mmol)
and Et3N (211 µL, 1.5 mmol) in CH2Cl2 (14 mL) at 0 °C. After 3 h, the reaction solution
was washed twice with sat. NH4Cl and the aqueous phase was extracted twice with
CH2Cl2. The combined organic phases were washed with brine, dried over Na2SO4,
filtered

and

concentrated

in

vacuo

to

afford

crude

tert-butyl

N-(4((tert-

butyldimethylsiyl)oxy)butyl)-N-(3-((triphenylmethyl)sufanyl)propyl)carbamate

as

an

orange oil and was used without further purification. IR ν (cm-1) 1693; 1H NMR (400
MHz, CDCl3) δ 0.04 (s, 6H), 0.88 (s, 9H), 1.39 (br s, 4H), 1.45 (br s, 2H), 1.53 (s, 9H),
2.13 (t, J = 7.6 Hz, 2H), 3.05 (br s, 4H), 3.58 (t, J = 5.6 Hz, 2H), 7.18-7.29 (m, 9H), 7.397.41 (m, 6H); 13C NMR (100 MHz, CDCl3) δ -5.1, 18.5, 25.4, 26.2, 27.6, 28.6, 29.6, 30.3,
46.5, 47.0, 63.0, 66.8, 79.3, 126.8, 128.1, 129.8, 145.1, 155.6.

TrS

Boc
N

tert-Butyl

N-(4-hydroxybutyl)-N-(3-((triphenylmethyl)sulfanyl)propyl)carbamate.

OH

TBAF (1.5 mL of 1 M solution in THF, 1.5 mmol) was added to a solution of crude tertbutyl

N-(4((tert-butyldimethylsiyl)oxy)butyl)-N-(3-((triphenylmethyl)sufanyl)

propyl)carbamate (1.4 mmol) in dry THF (5 mL) at 0 °C. The reaction mixture was
stirred overnight, allowing the reaction to warm to rt. Upon completion as determined by
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TLC analysis, the reaction was washed twice with sat. NaHCO3 and the combined
aqueous phases were extracted three times with Et2O. The combined organic layers were
washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The crude
material was purified by column chromatography (SiO2, 3:7, EtOAc:CH2Cl2) to give
tert-butyl

N-(4-hydroxybutyl)-N-(3-((triphenylmethyl)sulfanyl)propyl)carbamate

(673

mg, 98% over 2 steps) as a light yellow oil. IR ν (cm-1) 1669, 3426; 1H NMR (400 MHz,
CDCl3) δ 1.39 (s, 9H), 1.45-1.51 (m, 4H), 1.54-1.58 (m, 2H), 2.14 (t, J = 7.2 Hz, 2H),
2.29 (br s, 1H), 3.05 (br s, 4H), 3.60 (t, J = 5.6 Hz, 2H), 7.17-7.28 (m, 9H), 7.39-7.41 (m,
6H);

13

C NMR (100 MHz, CDCl3) δ 24.9, 28.0, 28.6, 29.6, 29.8, 46.6, 46.9, 62.4, 66.8,

79.6, 126.8, 128.1, 129.8, 145.0, 155.7. HRMS m/z cald [C62H79N2O6S2]+3 1011.5363,
observed 1011.5385.

TrS

Boc
N

O
O

N

N

14

4-(((tert-Butoxy)carbonyl)((3-((triphenylmethyl)sulfanyl)propyl))amino) butyl 1Himidazole-1-carboxylate (14).
added

to

a

1,1’-Carbonyldiimidazole (154 mg, 0.95 mmol) was

solution

of

tert-butyl

N-(4-hydroxybutyl)-N-(3-

((triphenylmethyl)sulfanyl)propyl) carbamate (320 mg, 0.63 mmol) and (i-Pr)2NEt (166
µL, 0.95 mmol) in dry CH2Cl2 (2 mL) at 0 °C. The mixture was stirred overnight,
allowing the reaction to warm to rt. The reaction solution was washed twice with water
and extracted once with CH2Cl2. The combined organic layers were washed twice with
sat. NH4Cl, once with brine, were dried over Na2SO4, filtered and concentrated in vacuo
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to afford crude 5 (350 mg, 92%) as a light yellow oil and was used without further
purification. IR ν (cm-1) 1686, 1760; 1H NMR (400 MHz, CDCl3) δ 1.39 (s, 9H), 1.521.61 (m, 4H), 1.70-1.77 (m, 2H), 2.15 (t, J = 7.2 Hz, 2H), 3.09 (br s, 4H), 4.40 (t, J = 6.6
Hz, 2H), 7.06 (s, 1H), 7.18-7.29 (m, 9H), 7.39-7.41 (m, 7H), 8.13 (s, 1H); 13C NMR (125
MHz, CDCl3) δ 24.6, 26.0, 28.2, 28.5, 29.5, 46.5 (2 C’s), 66.8, 68.1, 79.6, 117.2, 126.7,
128.0, 129.7, 130.8, 137.2, 144.9, 148.8, 155.4.

HRMS m/z cald [C35H42N3O4S]+

600.2891, observed 600.2892.

TrS

Boc
N

O

O
O

O

O

N
O

2-(2-(((4-(((tert-Butoxy)carbonyl)((3-((triphenylmethyl)sulfanyl)propyl))amino)
butoxy)carbonyl)oxy)ethoxy)-2,3-dihydro-1H-isoindole-1,3-dione.

DBU (434 µL,

2.80 mmol) was added to a solution of crude tert-butyl N-(4-hydroxybutyl)-N-(3((triphenylmethyl)sulfanyl)propyl)carbamate (1.64 g, 2.80 mmol) in dry MeCN (12 mL).
After stirring for 10 min, 2-(2-hydroxyethoxy)-2,3-dihydro-1H-isoindole-1,3-dione (579
mg, 2.80 mmol) was added and the reaction was stirred overnight. Upon completion, the
reaction was washed twice with sat. NH4Cl and the combined aqueous layers were
extracted three times with EtOAc. The combined organic layers were washed with brine,
dried over Na2SO4, filtered and concentrated in vacuo. The crude material was purified
by column chromatography (SiO2, 3:17, EtOAc:CH2Cl2) to give 2-(2-(((4-(((tertbutoxy)carbonyl)((3-((triphenylmethyl)sulfanyl)

propyl))amino)butoxy)carbonyl)oxy)

ethoxy)-2,3-dihydro-1H-isoindole-1,3-dione (350 mg, 60%) as a colorless oil. IR ν (cm136

1

) 1685, 1733, 1793; 1H NMR (400 MHz, CDCl3) δ 1.40 (s, 9H), 1.48-1.60 (m, 6H), 2.16

(t, J = 7.0 Hz, 2H), 3.06 (br s, 4H), 4.14 (t, J = 5.2 Hz, 2H), 4.43-4.44 (m, 4H), 7.18-7.28
(m, 9H), 7.39-7.41 (m, 6H), 7.69-7.72 (m, 2H), 7.91-7.81 (m, 2H); 13C NMR (100 MHz,
CDCl3) δ 24.6, 26.1, 28.2, 28.6, 29.5, 46.5, 46.6, 65.2, 66.8, 68.1, 75.7, 79.5, 123.8,
126.8, 128.0, 129.0, 129.7, 134.8, 145.0, 155.1, 155.5, 163.5.

HRMS m/z cald

[C42H47N2O8S]+ 739.3048, observed 739.3058.

TrS

Boc
N

O
O

O

ONH2

15
N-(4-(((2-(aminooxy)ethoxy)carbonyl)oxy)butyl)-N-((tert-butoxy)carbonyl)-3((triphenylmethyl)sulfanyl)propan-1-amine (15). Hydrazine monohydrate (356 µL,
7.3 mmol) was added to a solution of 2-(2-(((4-(((tert-butoxy)carbonyl)((3((triphenylmethyl)sulfanyl)propyl))amino)butoxy)carbonyl)

oxy)ethoxy)-2,3-dihydro-

1H-isoindole-1,3-dione (1.08 g, 1.5 mmol) in CH2Cl2at 0 °C and stirred for 2 h. When
complete, the white precipitate was removed by filtration and the filter cake was washed
with ample CH2Cl2. The filtrate was concentrated in vacuo to afford 6 (899 mg, 99%) as
a colorless oil and was used without further purification. IR ν (cm-1) 1687, 1744, 3323;
1

H NMR (400 MHz, CDCl3) δ 1.39 (s, 9H), 1.50-1.62 (m, 6H), 2.14 (t, J = 7.2 Hz, 2H),

3.05 (br s, 4H), 3.85 (t, J = 4.2 Hz, 2H), 4.13 (t, J = 6.2 Hz, 2H), 4.32 (t, J = 4.4 Hz, 2H),
5.52 (br s, 2H), 7.18-7.29 (m, 9H), 7.39-7.41 (m, 6H);

13

C NMR (100 MHz, CDCl3)

δ 24.7, 26.2, 27.5, 28.6, 29.5, 46.7 (2 C’s), 65.5, 66.8, 68.0, 73.4, 79.5, 126.8, 128.0,
129.8, 145.0, 155.5. HRMS m/z cald [C68H89N4O12S2]+3 1217.5918, observed 1217.5917.
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5.3.2. Amine-free Linker
TrS

OH

6-(Tritylthio)hexan-1-ol. 6-bromohexanol (0.526 g, 2.90 mmol), triphenylmethanethiol
(0.802 g, 2.90 mmol), and K2CO3 (0.802 g, 5.80 mmol) were added to a 1:1 mixture of
ethanol:water (15.0 mL) and the reaction was heated to 90 °C for 18 h. After cooling to
rt, the reaction was quenched with 1M HCl and extracted three times with CH2Cl2. The
combined organic layers were washed with water, brine, dried over anhydrous Na2SO4,
filtered, and concentrated in vacuo to give 6-(tritylthio)hexan-1-ol (0.88 g, 82%) as a
yellow oil and was used without further purification. IR ν (cm-1) 3362; 1H NMR (500
MHz, CDCl3) δ 1.19-1.30 (m, 4H), 1.37-1.43 (m, 2H), 1.45-1.50 (m, 2H), 2.14 (t, J = 7.5
Hz, 2H), 3.58 (t, J = 6.5 Hz, 2H), 7.19-7.29 (m, 9H), 7.40-7.42 (m, 6H); 13C NMR (100
MHz, CDCl3) δ 25.5, 28.8, 32.1, 32.7, 63.0, 66.6, 126.7, 128.0, 129.8, 145.2.

O
TrS

O
17

N

N

6-(Tritylthio)hexyl 1H-imidazole-1-carboxylate (17). 1,1’-carbonyldiimidazole (1.27
g, 7.86 mmol) was added to a solution of N,N-diisopropylethylamine (1.02 g, 7.86 mmol)
and 6-(tritylthio)hexan-1-ol (1.97 g, 5.24 mmol) in CH2Cl2 (25 mL) at 0 °C and was
stirred overnight. The reaction mixture was washed twice with water and extracted once
with CH2Cl2. The combined organic layers were washed twice with sat. NH4Cl, once
with brine, were dried over anhydrous Na2SO4, and concentrated in vacuo to give 8 as a
yellow oil and was used without further purification. IR ν (cm-1) 1768; 1H NMR (500
MHz, CDCl3) δ 1.26-1.34 (m, 4Hz), 1.38-1.44 (m, 2H), 1.68-1.73 (m, 2H), 2.16 (t, J =
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7.0 Hz, 2H), 4.35 (t, J = 6.5 Hz, 2H), 7.11 (s, 1H), 7.19-7.29 (m, 9H), 7.40-7.42 (m, 6H),
8.11 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 25.4, 28.4, 28.6, 31.7, 66.6, 68.4, 117.2,
126.7, 128.1, 129.7, 130.8, 137.2, 145.1, 148.9; HRMS m/z cald [C29H32N2O2S]+
471.2101, observed 471.2096.

O
TrS

O

O

O

O
N

O
2-((6-(Tritylthio)hexyl)oxy)isoindoline-1,3-dione. DBU (1.65 mL, 11.1 mmol) was
added to a solution of crude 6-(tritylthio)hexyl 1H-imidazole-1-carboxylate (5.21 g, 11.1
mmol) in dry MeCN (50 mL). After stirring for 10 min, N-(2-Hydroxyethyl)phthalimide
(2.29 g, 11.1 mmol) was added and the reaction was stirred overnight. Upon completion,
the reaction was washed twice with sat. NH4Cl and the combined aqueous layers were
extracted three times with EtOAc. The combined organic layers were washed with brine,
dried over Na2SO4, filtered and concentrated in vacuo. The crude material was purified
by column chromatography (SiO2, 3:7 Hex:EtOAc) to give 2-((6(tritylthio)hexyl)oxy)isoindoline-1,3-dione (4.48 g, 66% over 2 steps) as a clear oil. IR ν
(cm-1) 1735, 1793; 1H NMR (500 MHz, CDCl3) δ 1.19-1.27 (m, 4H), 1.36-1.41 (m, 2H),
1.54-1.59 (m, 2H), 2.13 (t, J = 7.5 Hz, 2H), 4.08 (t, J = 7.0 Hz, 2H), 4.43-4.47 (m, 4H),
7.19-7.29 (m, 9H), 7.40-7.42 (m, 6H), 7.73-7.75 (m, 2H), 7.83-7.84 (m, 2H); 13C NMR
(100 MHz, CDCl3) δ 25.4, 28.4, 28.6, 32.0, 65.2, 66.6, 68.4, 75.7, 123.8, 126.7, 128.0,
129.0, 129.8, 134.8, 145.2, 155.1, 163.5.
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O
TrS

O

O

ONH2

18
O-(6-(Tritylthio)hexyl)hydroxylamine (18). Hydrazine monohydrate (2.16 g, 43.11
mmol) was added to a solution of 2-((6-(tritylthio)hexyl)oxy)isoindoline-1,3-dione (5.25
g, 8.62 mmol) in CH2Cl2 (100 mL) at 0 °C and stirred for 2 h. When complete, the white
precipitate was removed by filtration and the filter cake was washed with ample CH2Cl2.
The filtrate was concentrated in vacuo to afford 9 (4.06 g, 98%) as a colorless oil and was
used without further purification. IR ν (cm-1) 1749, 3334; 1H NMR (500 MHz, CDCl3) δ
1.21-1.29 (m, 4H), 1.36-1.41 (m, 2H), 1.54-1.61 (m, 2H), 2.14 (t, J = 7.0 Hz, 2H), 3.86
(t, J = 4.0 Hz, 2H), 4.07 (t, J = 6.5 Hz, 2H), 4.33 (t, J = 4.5 Hz, 2H), 5.52 (s, 1H), 7.197.29 (m, 9H), 7.40-7.41 (m, 6H); 13C NMR (100 MHz, CDCl3) δ 25.4, 28.5, 28.7, 31.9,
65.4, 66.6, 68.2, 73.4, 126.7, 127.9, 129.8, 145.2, 155.6; HRMS m/z cald [C28H34NO4S]+
480.2203, observed 480.2206.
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5.4.

CHAPTER 4 EXPERIMENTAL PROCEDURES

5.4.1. Preparation of Fe@Au@LS-anthracene NPs
TGA calculation for LS loading
The amount of linker per milligram of NP was calculated based off TGA data
seen in Chapter 4. Briefly:

a. Total amount of LS1-anthracene lost is equivalent to total amount loaded onto NPs.
This amount is converted to mmol using molecular weight (465.2 g/mol).
b. Total amount of Fe@Au NPs is calculated by subtracting the amount of LS1anthracene lost from the total weight.
c. Conversion: if 4.3 x 10-4 mmol LS1-anthracene loaded for 2.2555 mg Fe@Au NPs,
then 1.9 x 10-4 would be loaded onto 1 mg Fe@Au NPs.

Calculations determined the amount of LS1-anthracene loaded onto 1 mg of NP to be
0.0002 mmol. In our preparation, we used 100 times excess linker, or 0.02 mmol, per
milligram NP.

Preparation of protected LS1-anthracene 19
Anthracene-CHO (296.4 mg, 1.35 mmol) was added to 15 (820.6 mg, 1.35 mmol)
in CH2Cl2 (5 mL) at room temperature and stirred overnight. Upon completion as
determined by TLC analysis, the reaction concentrated in vacuo to afford 19 (1.08 g,
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99%) as an orange oil and was used without further purification. IR ν (cm-1) 1684, 1724,
1741; 1H NMR (500 MHz, CDCl3) major isomer δ 1.38 (s, 9H), 1.45-1.65 (m, 6H), 2.13
(t, J = 7.5 Hz, 2H), 3.04 (br s, 4H), 3.72 (t, J = 4.5 Hz, 2H), 4.13 (t, J = 6.5 Hz, 2H), 4.33
(t, J = 5.0 Hz, 2H), 4.50 (d, J = 6.5 Hz, 2H), 7.18-7.27 (m, 9H), 7.39-7.40 (m, 6H), 7.467.52 (m, 4H), 8.02 (d, J = 8.5 Hz, 2H), 8.17 (d, J = 8.5 Hz, 2H), 8.42 (s, 1H); 13C NMR
(100 MHz, CDCl3) major isomer δ 24.7, 25.4, 26.2, 28.6, 29.5, 43.3, 46.7 (2 C’s), 66.2,
66.5, 67.8, 71.3, 79.5, 124.0, 125.3, 126.4, 126.8, 127.4, 128.0, 129.5, 129.8, 130.3,
131.7, 134.3, 145.0, 149.6, 155.5.

Preparation of protected LS2-anthracene 23
Anthracene-CHO (495.4 mg, 2.25 mmol) was added to 18 (1.08 g, 2.25 mmol) in
CH2Cl2 (10 mL) at room temperature and stirred overnight. Upon completion as
determined by TLC analysis, the reaction concentrated in vacuo to afford 23 (1.53 g,
99%) as an orange oil and was used without further purification. IR ν (cm-1) 1669, 1744;
1

H NMR (400 MHz, CDCl3) major isomer δ 1.17-1.28 (m, 4H), 1.32-1.40 (m, 2H), 1.50-

1.66 (m, 2H), 2.11 (t, J = 9.0 Hz, 2H), 4.03 (t, J = 8.5 Hz, 2H), 4.32 (t, J = 6.5 Hz, 2H),
4.51 (d, J = 7.0 Hz, 2H), 7.19-7.29 (m, 9H), 7.39-7.41 (m, 6H), 7.46-7.50 (m, 4H), 8.02
(d, J = 10.0 Hz, 2H), 8.30 (d, J = 10.5 Hz, 2H), 8.42 (s, 1H); 13C NMR (100 MHz,
CDCl3): δ 25.2, 25.3, 28.5, 31.9, 66.0, 66.5, 68.0, 71.2, 124.0, 125.1, 126.2, 126.6, 127.2,
127.9, 128.4, 129.3, 129.7, 130.2, 131.5, 145.1, 149.4, 155.2.
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Preparation of LS-anthracene (20 and 24)
To prepare LS1-anthracene for loading onto Fe@Au NPs, protected LS1anthracene (364.8 mg, 0.45 mmol) was dissolved in CH2Cl2 (5 mL) at 0 °C. TFA (5 mL,
65 mmol) was added dropwise, followed by Et3SiH (215.5 µL, 1.35 mmol) added
dropwise. The mixture was stirred at 0 °C for 30 mins. Upon completion as determined
by TLC analysis, the reaction was warmed to rt, concentrated in vacuo, and used crude
immediately for addition to NPs. Both 20 and 24 followed this procedure.

Preparation of Fe@Au-LS-anthracene NPs (21 and 25)
LS1-anthracene 20 (112.32 mg, 0.24 mmol) was redissolved in CH2Cl2 (6.4 mL),
then added to a solution of rapidly stirring Fe@Au NPs (6 mg) in hexane (15 mL) over 4
hours, followed by precipitation with EtOH (40 mL).

NPs were pelleted via

centrifugation at 10K rpm for 15 minutes. The supernatant was discarded, the NPs were
redissolved in CH2Cl2 (5 mL) and precipitated with EtOH (45 mL). NPs were pelleted
via centrifugation at 10K rpm for 15 minutes, and the supernatant was discarded. This
washing process was performed 4 more times. After the final discard of supernatant, the
NPs were dried in vacuo and stored in solid form under nitrogen at rt until further use.
Both 21 and 25 were prepared in this manner.

5.4.2. AMF studies of Fe@Au@LS-anthracene (21 and 25)
Fe@Au@LS1-anthracene NPs 21 and Fe@Au@LS2-anthracene NPs 25 were
separately subjected to one 15-minute burst of AMF exposure at 500 A. After the
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exposure, the NPs were pelleted via centrifugation at 10K rpm for 5 min, and the
supernatant was analyzed using MALDI-TOF.
To confirm initial loading of LS2-anthracene, freshly loaded Fe@Au@LS2anthracene NPs 25 were incubated in 400 µL 0.1M DTT for 2 h at rt, pelleted via
centrifugation at 10K rpm for 5 min, and the supernatant was analyzed using MALDITOF.

5.4.3. Preparation of Fe@Au@LS-PEG NPs
Preparation of protected LS1-FITC 26
FITC-CHO (112.2 mg, 0.24 mmol) was added to a 15 (143.3 mg, 0.24 mmol) in
9:1 CHCl3:MeOH (3 mL) at room temperature and stirred overnight. Upon completion
as determined by TLC analysis, the reaction concentrated in vacuo to afford 26 (226.2
mg, 90%) and was used without further purification.

1

H NMR (500 MHz, DMSO-d6)

δ 1.29 (s, 9H), 1.31- 1.52 (m, 6H), 1.57-1.76 (m, 2H), 2.06 (br s, 2H), 2.17-2.22 (m, 3H),
2.96 (br s, 4H), 3.48-3.56 (m 2H), 3.80-3.84 (m, 2H), 4.02-4.06 (m, 2H), 4.35-4.26 (m,
2H), 6.55-6.61 (m, 4H), 6.67 (s, 2H), 7.15-7.31 (m, 17H), 7.82-7.84 (m, 1H), 8.22 (s,
1H), 10.12 (brs, 2H).

Preparation of protected LS2-FITC 27
FITC-CHO (522.7 mg, 1.1 mmol) was added to a 18 (526 mg, 1.1 mmol) in 9:1
CHCl3:MeOH (5 mL) at room temperature and stirred overnight. Upon completion as
determined by TLC analysis, the reaction concentrated in vacuo to afford 27 (915.4 mg,
89%) and was used without further purification. 1H NMR (500 MHz, DMSO-d6) δ 1.07-
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1.23 (m, 4H), 1.27-1.29 (m, 2H), 1.47-1.49 (m, 2H), 1.90 (br s, 2H), 2.01-2.09 (m, 4H),
2.51 (s, 1H), 3.58-3.62 (m, 2H), 3.69-3.71 (m, 2H), 3.82-3.86 (m, 1H), 3.98-4.01 (m,
2H), 4.21-4.22 (m, 2H), 5.79 (br s, 1H), 6.57-6.65 (m, 4H), 6.70 (s, 2H), 7.16-7.24 (m,
11H), 7.28-7.39 (m, 6H), 7.85-7.87 (m, 1H), 8.10 (s, 1H), 10.12 (br s, 2H).

Preparation of LS-FITC (28 and 29)
To prepare LS1-FITC for loading onto Fe@Au NPs, protected LS1-FITC (95.7
mg, 0.09 mmol) was dissolved in CH2Cl2 (1 mL) at 0 °C. TFA (250 µL, 13 mmol) was
added dropwise, followed by Et3SiH (43 µL, .27 mmol) added dropwise. The mixture
was stirred at 0 °C for 30 mins. Upon completion as determined by TLC analysis, the
reaction was warmed to rt, concentrated in vacuo, and used crude immediately for
addition to NPs. Both 28 and 29 followed this procedure.

Preparation of Fe@Au-LS-FITC-PEG NPs (30 and 31)
Following a modified procedure by Menichette et al.,13 PEG-SH (82.6 mg, 0.09
mmol) was added to LS1-FITC 28 (18 mg, 0.09 mmol) in 9:1 CHCl3:MeOH (10 mL).
This solution was added to rapidly stirring NPs (5 mg) in CHCl3 (10 mL), and the
solution was stirred rapidly overnight.

The NPs were concentrated in vacuo and

redissolved in EtOH (50 mL). NPs were pelleted via centrifugation at 10K rpm for 15
minutes. The supernatant was discarded, the NPs were redissolved in H2O (50 mL) under
sonication, pelleted via centrifugation at 10K rpm for 15 minutes, and the supernatant
was discarded. The NPs were resissolved in saturated sodium bicarbonate (50 mL) under
sonication, pelleted via centrifugation at 10K rpm for 15 minutes, and the supernatant

145

was discarded. The NPs were resissolved in 1X PBS buffer (50 mL, pH = 7.4) under
sonication, pelleted via centrifugation at 10K rpm for 15 minutes, and the supernatant
was discarded. The NPs were resissolved in DI water (50 mL) under sonication, pelleted
via centrifugation at 10K rpm for 15 minutes, and the supernatant was discarded. This
washing process with water was performed twice. After the final discard of supernatant,
the NPs were lyophilized and stored in solid form under nitrogen at rt until further use.
Both 30 and 31 were prepared in this manner. Fe@Au-LS1-FITC-PEG NPs 30 were
characterized via UV-vis spectroscopy, ζ-potential, DLS, and SEM. UV-vis showed a
characteristic surface plasmon resonance band at 531 nm, indicating the presence of gold.
The ζ-potential was 12.6 ± 0.212 mV. This is not surprising because both LS1-FITC and
PEG are neutral in water. The DLS reading was 229.5 ± 0 nm, but the particles have an
average diameter of 23 ± 7 nm based on SEM imaging (Figure 4.13).

5.4.4. AMF studies of Fe@Au@LS-FITC-PEG NPs
A fresh batch of Fe@Au@LS1-FITC-PEG NPs 30 and Fe@Au@LS2-FITC-PEG
NPs 31 were separately subjected to four sequential 15-minute bursts of AMF exposure
at 500 A in 1 mL 1X PBS buffer (pH 7.4). After each exposure, the NPs were pelleted
via centrifugation at 10K rpm, 5 min, the supernatant was added to 2 mL fresh 1X PBS
buffer in a cuvette, and then analyzed using a fluorometer. Before each AMF exposure, 1
mL of the liquid in the cuvette was added to the NP pellet and resuspended. After the last
reading, an aliquot of the supernatant was analyzed via MALDI-TOF (Figure 3e and 3f),
then the NPs were incubated with 400 µL 0.1M DTT for 2 h at rt, pelleted via
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centrifugation at 10K rpm, 5 min, and then analyzed using a fluorometer. The DTT
fluorescence reading was deemed “100% release”, and each reading prior gave % release
based on this reading. Each linker system testing was done in triplicate.
A fresh batch of Fe@Au@LS1-PEG NPs 30 also was incubated for 2 hours, at 37
°C and at 50 °C, then incubated with 400 µL 0.1M DTT for 2 h at rt followed by analysis
using a fluorometer. The DTT fluorescence reading was deemed “100% release”, and
each reading prior gave % release based on this reading. Each temperature study was
performed in triplicate.

5.4.5. Preparation of GNP@LS1-FITC NPs
LS1-FITC 28 (118.7 mg, 0.16 mmol) in 9:1 CHCl3:MeOH (20 mL) was added to
rapidly stirring NPs (163.9 mg) in CHCl3 (50 mL), and the solution was stirred rapidly
overnight. The NPs were concentrated in vacuo and redissolved in EtOH (50 mL). NPs
were pelleted via centrifugation at 10K rpm for 15 minutes.

The supernatant was

discarded, the NPs were redissolved in H2O (50 mL) under sonication, pelleted via
centrifugation at 10K rpm for 15 minutes, and the supernatant was discarded. The NPs
were resissolved in saturated sodium bicarbonate (50 mL) under sonication, pelleted via
centrifugation at 10K rpm for 15 minutes, and the supernatant was discarded. The NPs
were resissolved in 1X PBS buffer (50 mL, pH = 7.4) under sonication, pelleted via
centrifugation at 10K rpm for 15 minutes, and the supernatant was discarded. The NPs
were resissolved in DI water (50 mL) under sonication, pelleted via centrifugation at 10K
rpm for 15 minutes, and the supernatant was discarded. This washing process with water
was performed twice. After the final discard of supernatant, the NPs were lyophilized
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and stored in solid form under nitrogen at rt until further use. GNP@LS1-FITC NPs
were characterized via ζ-potential, DLS, and SEM. ζ-potential showed a surface charge
of -20.6 ± 1.63 mV. DLS readings gave an average hydrodynamic diameter of 226.8 ±
26.77 nm, and SEM also shows aggregation of that size (Chapter 4, Figure 4.18a). Each
individual particle, though, was much smaller, as seen in Figure 4.18b.

5.4.6. AMF Studies of Dual NP system
For the dual NP system, 5 mg GNP@LS1-FITC was combined with an equal
amount of MNP by weight (1:1), twice the amount of MNP by weight (1:2), and three
times the amount of MNP by weight (1:3). Each freshly prepared ratio was subjected to
four sequential 15-minute bursts of AMF exposure at 500 A in 1 mL 1X PBS buffer (pH
7.4). After each exposure, the NPs were pelleted via centrifugation at 10K rpm for 5 min,
the supernatant was added to 2 mL fresh 1X PBS buffer in a cuvette, and then analyzed
using a fluorometer. Before each AMF exposure, 1 mL of the liquid in the cuvette was
added to the NP pellet and resuspended. After each exposure, the NPs were pelleted via
centrifugation at 10K rpm for 5 min, and the supernatant was analyzed using a
fluorometer. After the last reading, the NPs were incubated with 400 µL 0.1M DTT for 2
h at rt, pelleted via centrifugation at 10K rpm for 5 min, and the supernatant was analyzed
using a fluorometer. The DTT fluorescence reading was deemed “100% release”, and
each reading prior gave % release based on this reading. Each dual NP system testing
was done in triplicate.
A freshly prepared batch of each ratio of the dual NP system was also subjected to
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AMF exposure at 300 A. The method remained the same as previously described, but the
amperage was lowered to 300 A.
A freshly prepared batch of each ratio was incubated at 37 °C for 2 hours, pelleted
via centrifugation at 10K rpm for 5 min, and the supernatant was analyzed using a
fluorometer. The NPs were then incubated with 400 µL 0.1M DTT for 2 h at rt, pelleted
via centrifugation at 10K rpm for 5 min, and the supernatant was analyzed using a
fluorometer. The DTT fluorescence reading was deemed “100% release”, and each
reading prior gave % release based on this reading.
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SK Biladeau, WR Richmond, S Laulhé, S.; MH Nantz. Isotopically coded Nmethoxy amide reagents for GC-MS profiling of carbonyl compounds via mass
spectral tag generation. Anal. Methods, 2016, 8, 3704-3710.

My first two years of graduate school were devoted to a project unrelated to the present
thesis. The focus during this time was synthesis and application of an isotopically
labeled reagent for chemoselective capture of carbonyls for multiplex analysis. This
research served as a platform for me to experience multistep synthesis, methods of
compound purification, spectral analyses, and aminooxy chemistry, which came in handy
once I began my thesis work. I have included the publication that resulted from the
efforts during this time. The work shows how we designed a reagent N-methoxy-N-(2aminooxyethyl)-propionate (MAP) to increase stability toward hydrolysis and acyl
transfer. Because amides do not readily undergo α-cleavage as easily as esters, we used a
methoxy amine moiety so that, upon α-cleavage, the nitrogen radical formed would be
more stable, thus promoting α-cleavage (Scheme 2). In this manuscript, we describe the
synthesis and application of MAP using a variety of carbonyl compounds to show its
superiority.

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

A.2.

NMR spectra of key intermediates

H 2N

OTBS
11

193
1

H NMR of 11, 400 MHz, CDCl3

TMS

H 2N

OTBS
11

194
13

C NMR of 11, 100 MHz, CDCl3

195
FT-IR with ATR of 11

TrS

H
N

OTBS
13

196
1

H NMR of 13, 400 MHz, CDCl3

TrS

H
N

OTBS
13

197
13

C

NMR of 13, 100 MHz, CDCl3

198
FT-IR with ATR of 13

TrS

Boc
N

O
O

N

N

14

199

CH2Cl2

1

H NMR of 14, 400 MHz, CDCl3

TMS

TrS

Boc
N

O
O

N

N

14

200
13

C NMR of 14, 100 MHz, CDCl3

201
FT-IR with ATR of 14

TrS

Boc
N

O
O

O

ONH2

15

CH2Cl2
TMS
202
1

H NMR of 15, 400 MHz, CDCl3

TrS

Boc
N

O
O

O

ONH2

15

203
13

C NMR of 15, 100 MHz, CDCl3

204
FT-IR with ATR of 15

O
TrS

O

N

TMS
N

17

205
1

H NMR of 17, 400 MHz, CDCl3

O
TrS

O

N

N

17

206
13

C

NMR of 17, 100 MHz, CDCl3

207
FT-IR with ATR of 17

O
TrS

O

O

ONH2

18

TMS

CH2Cl2
208
1

H NMR of 18, 500 MHz, CDCl3

O
TrS

O

O

ONH2

18

209

CH2Cl2

13

C NMR of 18, 100 MHz, CDCl3

210
FT-IR with ATR of 18

A.3.

List of abbreviations

h = hour
rt = room temperature
mmol = millimole
mg = milligram
TLC = thin layer chromatography
rb = round bottom
rpm = revolutions per minute
EtOH = ethanol
CH2Cl2 = dichloromethane
CHCl3 = chloroform
TFA = trifluoroacetic acid
MeOH = methanol
nm = nanometer
MRI = magnetic resonance imaging
NMR = nuclear magnetic resonance
FTIR = fourier transform infrared radiation
HRMS = high resolution mass spectrometry
ATR = attenuated total reflectance
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